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Abstract
Chronic pain associated with painful diabetic peripheral neuropathy (DPN) can be 
difficult to manage, with pharmacological treatment not always providing adequate 
relief, trouble maintaining pain relief, or side effects from the treatments. There are 
few comparisons of drugs that are either licensed for DPN or recommended in the 
British national formulary (BNF). In an attempt to gain a clearer picture of the impact 
of pain associated with painful DPN, this thesis study measured quality of life, 
cognitive function, and subjective sleep along with the pain reducing effects and 
effects on cognitive function of pregabalin, duloxetine and amitriptyline. These three 
drugs are categorised in different classes of drug and have differing mechanisms of 
action on pain and in the central nervous system.
Patients were recruited from two hospitals, with a total of 83 patients randomised. The 
study was conducted over a period of 36 days including 3 residential visits where 
cognitive function and other measures were recorded.
Baseline measures of pain were associated with reduced quality of life, highlighting 
the impact of pain on this patient population. Baseline measures of pain also 
correlated with subjective sleep quality and subjective daytime sleepiness, further 
highlighting how pain affects these patients.
All three treatments reduced pain severity as measured by the Brief Pain Inventory 
(BPI) from visit 1 (baseline) to visit 2 (low dose) and no treatment appeared to be 
superior with regards to analgesic efficacy.The effects of each drug on cognitive 
function were modest and in keeping with their known actions on neurotransmission, 
although the negative effects of amitriptyline were fewer than anticipated. All three
treatments improved measures of subjective sleep and reduced daytime sleepiness. 
Again, no one treatment was superior. Although the treatments reduced pain and 
improved sleep there was no evidence of improved quality of life within the duration 
of the study.
This study, a comparison of the three main treatments for painful DPN, has revealed 
that all three treatments are beneficial, and any impact on cognitive function was 
modest. Correlations between pain and subjective sleep and quality of life allude to 
the importance of the effective pain management in this patient population.
The study presented in this thesis was funded by an unrestricted grant from Pfizer, 
and there are no conflicts of interest.
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Chapter 1: Introduction
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1. Diabetes Mellitus
Diabetes mellitus (DM) is a metabolic disorder characterised by chronic hyperglycaemia. 
Diabetes is a serious and chronic illness. Wild, et al.,(2004) conducted an assessment of the 
global mortality rate attributable to diabetes for the year 2000. It was estimated that in the 
year 2000 7.5 million people with diabetes died, 4.6 million were assumed to have died from 
causes other than diabetes, whilst 2.9 million were estimated to have died from diabetes itself.
There are two major types of diabetes, type 1 and type 2. Type 1 DM is an autoimmune 
disorder resulting from the destruction of the beta cells that produce insulin, and thus patients 
with type 1 require exogenous insulin for survival. Type 2 DM is the most common form of 
diabetes (Horikawa, Oda et al. 2000; Yates, Davies et al. 2009). Type 2 DM results from the 
body not secreting enough insulin or being resistant to its action. Type 2 DM can be 
controlled by diet alone, but some patients require pharmacological intervention. Patients 
with either type of diabetes may require exogenous insulin, the use of insulin does not define 
the type of diabetes that the patient has. Without the regulatory action of insulin the levels of 
glucose in the blood can become abnormally elevated (hyperglycaemia), or abnormally 
lowered (hypoglycaemia).
Diabetes rarely occurs in isolation, and patients often suffer from complications such as 
cardiovascular disease, kidney disease (nephropathy), nerve damage (neuropathy), and foot 
problems.
1.1. Global prevalence of diabetes
Currently, it is only possible to estimate the prevalence of diabetes worldwide due to 
the lack of data available in some countries, particularly developing countries. In 
future years it may be possible to produce more precise numbers with improved data
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collection and record-keeping. Wild et al., (2004) estimated the global prevalence of 
diabetes for the year 2000 and 2030. This was estimated using data from a limited 
number of countries, which was then extrapolated to 191 World Health Organisation 
member states, using the United Nations’ population estimates for 2000 and 2030. 
The prevalence of diabetes worldwide was estimated to be 2.8% in 2000 rising to 
4.4% in 2030. The total number of people with diabetes in 2000 was estimated to be 
171 million, and this is projected to rise to 366 million in 2030. This data does not 
distinguish between type 1 and type 2 diabetes. When considering the prevalence of 
diabetes, it is important to keep in mind that there is a sizeable number of people who 
have diabetes, but are as yet undiagnosed. In a position statement by diabetes UK in 
2006, they estimate that 75,000 individuals in the UK remain undiagnosed. This 
estimation came from previous study data and was extrapolated to the whole of the 
UK to reach the 75,000 value (Forouhi, Merrick et al. 2006).
2. Painful Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy (DPN) is a serious, and often disabling, complication 
of diabetes. There are various neuropathies which can develop but DPN (also referred 
to as distal symmetric polyneuropathy) is the most common type of diabetic 
neuropathy (Greene, Stevens et al. 1999). DPN occurs through damage to the 
peripheral nervous system leading to various symptoms which can be painful, result in 
amputation, and contribute to mortality. DPN can be divided into Diabetic Peripheral 
Neuropathy, which includes sensory loss, but the symptoms are painless, and Painful 
Diabetic Peripheral Neuropathy (painful DPN), where as well as sensory loss the 
symptoms are painful.
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2.1. Pain
Pain is defined by the International Association for the Study of Pain (lASP) as “An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Merskey and Bogduk 1994).
2.2. The sensation of pain
The sensation of pain is essential to our existence as it alerts us to situations, which in 
some cases could be life-threatening. Baxter and Olszewski (1960) illustrate this by 
reporting the case of Miss C. She had congenital universal insensitivity to pain (CUIP) 
and died at the age of 29. During her life she suffered repeated injuries including 
third-degree bums from radiators and sunburn. They summarise that her lack of pain 
awareness led to extensive skin and bone trauma which contributed to her death.
2.3. Acute pain and Chronic pain
Acute pain is usually as a result of bodily damage. The sensation of pain is an 
important biological function which alerts the individual, and causes the individual to 
take preventative action and seek medical attention as required (Gatchel 1996).
The British Pain Society define chronic pain as ‘continuous, long-term pain of more 
than 12 weeks or after the time that healing would have been thought to have occurred 
in pain after trauma or surgery’. Chronic pain is defined by the lASP as pain that 
persists beyond the normal time of healing and that three months is the most 
convenient point of division between acute and chronic pain for non-malignant pain 
(Merskey and Bogduk 1994).
Turk and Melzack (2001) suggest that the classification of acute or chronic pain is 
inadequate as it does not include recurrent acute pain (e.g. migraines) or pain
16
associated with progressive diseases such as metastatic cancer. The authors suggest 
including acute recurrent, and chronic progressive to the pain classifications. However 
there is no one universally accepted system for classifying pain.
Unmanaged pain has a profound impact on quality of life and inadequate efforts at 
controlling pain are unacceptable to the individuals experiencing pain (Katz 2002).
Treating and managing chronic pain remains challenging and little is known about the 
long-term effects of treatment (Finnerup, Sindrup et al. 2007).
2.4. Pain measurement
The measurement of pain is essential for the study of pain mechanisms and for the 
evaluation of methods to control pain (Turk and Melzack 2001).
However, pain is difficult to measure due to its subjective nature and the fact that it 
can vary in intensity throughout a given period. Pain can be measured by either asking 
the individual to describe their pain or choose from a number of descriptors such as 
‘throbbing’, ‘stabbing’, ‘burning’, etc, or by assigning a numerical value to the pain 
experienced. Where change in pain is being recorded a scale would be utilised. These 
scales are generally presented as an 11-point numerical rating scale (NRS) from 0-10, 
or a visual analogue scale (VAS) which is a 100mm long line with ‘no pain’ on one 
end and ‘worst pain’ at the other end, the individual places a mark on the line and a 
measurement can then be made (Williamson and Hoggart 2005).
The Brief Pain Inventory (BPI) is a NRS which was originally designed to measure 
cancer pain (Cleeland and Ryan 1994). It assesses pain over a 24hr period asking 
patients to rate their pain on a series of questions from 0 -1 0 , where 0 represents ‘no 
pain, whereas 10 equals ‘pain as bad as you can imagine’. Individual scores can be
17
used to assess pain change and a pain severity score and a pain interference score can 
also be calculated. The BPI has also been validated for chronic non-malignant pain 
(Tan, Jensen et al. 2004).
The McGill Pain Questionnaire (MPQ) was developed to measure pain in a 
quantitative method, with the resulting data being suitable for statistical analysis 
(Melzack 1975). The MPQ results in three major measures which are: (1) a pain 
rating index - patients are given a list of descriptor words which they select as 
appropriate to their pain, numerical values are assigned to produce the pain rating 
index; (2) the number of words chosen; (3) the present pain intensity, which is based 
on a 1-5 intensity scale. The Short-Form McGill Pain Questionnaire (SF-MPQ) was 
developed to assess pain in a shorter time than the original MPQ (Melzack 1987). 
Patients are given 15 words that describe or are related to pain and are asked to select 
‘none’, ‘mild’, ‘moderate’, or ‘severe’ in relation to these descriptors. Numerical 
values are assigned and scored to produce three scores based on sensory, affective and 
total descriptor words. The SF-MPQ also includes a VAS with ‘no pain’ on the left 
and ‘worst possible pain’ on the right. In addition to these measures, patient’s are 
asked to rate their pain intensity from 0 = ‘no pain’ to 5 = excruciating. The author 
concludes that the SF-MPQ is a useful instrument, which should not replace the 
original but is for use in studies where time is limited or less information is required.
2.5. The characteristics of painful diabetic peripheral neuropathy
Peripheral neuropathic pain is defined by the lASP as “pain initiated or caused by a 
primary lesion or dysfunction in the nervous system” (Merskey and Bogduk 1994)
One of the classic characteristics of DPN is that it affects the distal nerves resulting in 
a ‘stocking pattern’ effect of sensory loss. This starts at the toes, moving up the leg,
18
and can then start at the fingertips and in extreme cases affect other parts of the body. 
This sensory loss can result in further injury to the patients, as they can damage the 
affected areas but not realize that they have done so. Patients can also suffer from 
allodynia where areas of skin are abnormally sensitive and unexpected stimuli cause 
pain. In a recent review of the literature, Huizinga and Peltier (2007) describe the most 
prevalent pain experienced by patients with painful DPN as tingling, burning, 
electrical, or deep aching pain. Other descriptor words are used by patients and in one 
diabetic clinic attended by the researcher, a patient described the pain as ‘mice 
nibbling at the feef. These sensations of pain can be very distressing for the patient. 
Galer et al., (2000) assessed 105 patients with painful DPN and identified pain as a 
significant medical issue which impacts on patient’s quality of life.
2.6. Prevalence of diabetic peripheral neuropathy and painful diabetic 
peripheral neuropathy.
Varying rates of prevalence have been reported, and studies don’t always distinguish 
between DPN and painful DPN. One estimate is that over 50% of diabetics who have 
had diabetes for longer than 25 years are affected by diabetic neuropathy (not 
necessarily DPN) (Pirart 1977). There is also the problem of patients who are currently 
asymptomatic and therefore not included in the prevalence rates.
Prevalence rates differ in the literature, this has been attributed to varying opinions on 
diagnostic criteria, therefore making prevalence rates hard to establish (Schmader 
2002). Table 1 shows prevalence rates for DPN, and Table 2 displays prevalence rates 
for painful DPN.
19
With the prevalence of diabetes set to increase dramatically, the prevalence of DPN 
will also increase, therefore research into this difficult to treat complication is of great 
importance.
20
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3. Treatment
Currently, painful diabetic peripheral neuropathy is only treatable using palliative 
treatments, Greene et ah, (1999), and there are no treatments which restore the nerve 
function (Spruce, Potter et al. 2003). Patients often require pharmacological treatment 
to alleviate the pain associated with painful DPN.
3.1. Amitriptyline
Amitriptyline is a tricyclic antidepressant (TCA) which inhibits the reuptake of 
noradrenaline and serotonin (5-hydroxy tryptamine). Antidepressants have been used in 
the management of neuropathic pain for 30 years (Collins, Moore et al. 2000). The 
National Institute for Health and Clinical (NICE) guidelines for managing painful 
neuropathy were updated in early 2010, and suggest using amitriptyline as an 
analgesic in patients suffering from painful neuropathy. Amitriptyline does not have a 
licensed indication for the treatment of painful DPN. It is, however recommended by 
the British National Formulary (BNF) and is often used to treat pain in this condition. 
Conversely, the Beer’s list (Beers, 1997), lists amitriptyline as a drug that is 
inappropriate for use in elderly people because of its anticholinergic effects, this 
should be taken into consideration with painful DPN as patients are often elderly.
The relief of neuropathic pain with amitriptyline is purported to be through the 
inhibition of the reuptake of noradrenaline and serotonin (5-hydroxy tryptamine) in 
the brainstem and spinal cord which facilitates the inhibition of pain pathways.
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Although tricyclics remain the first choice of treatment for neuropathy, their use is 
limited by their side effects (Boulton, Malik et al. 2004).
Amitriptyline is relatively non-selective in its mechanism of action and therefore 
produces a number of side effects. Widely reported are anticholinergic effects 
(Khawam et al., 2006), which include dry mouth and blurred vision. Sedative effects 
are also reported, as well as problems with interaction with other drugs. These side 
effects can be more impairing and difficult to manage in an elderly population.
3.1.1. Amitriptyline and its use in painful DPN
Hall et al., (2006) identified 4719 patients with painful diabetic neuropathy using the 
General Practice Research Database (GPRD). They further identified the five most 
frequently prescribed medications for neuropathic pain which were amitriptyline, 
carbamazepine, coproxamol, codeine with paracetamol, and codydramol. Of the 4719 
patients, 2336 were prescribed one of these drugs in their initial treatment, with 
amitriptyline the favoured treatment at 24.2%. Tolle et al., (2006) surveyed 140 
patients with painful DPN. Questionnaires included the Short-Form Brief Pain 
Inventory and their physicians provided information on current medications, 26% of 
these patients were prescribed amitriptyline.
In a trial comparing gabapentin with amitriptyline in reducing pain associated with 
painful DPN, Dallocchio et al., (2000), found that gabapentin produced greater 
reductions in pain scores as compared to amitriptyline, and that adverse events were 
more frequent in the subjects taking amitriptyline. Pain reduction was assessed in 
twenty five type 2 diabetics over a period of 12 weeks.
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Conversely a study by Morello et al (1999) did not find a significant difference in the 
reduction in neuropathic pain when comparing gabapentin with amitriptyline. This 
may be due to the different age group (average age of 60 compared to under 60 in the 
Dallocchio study), or the different doses of drugs used, or the gender difference with 
the majority of the Morello study subjects being male.
3.1.2. Cognitive function and amitriptyline
A concern when prescribing amitriptyline, especially in the elderly, is that its 
anticholinergenic and sedative properties have the potential to interfere with memory 
and cause general drowsiness. The hypothesis that amitriptyline would exacerbate 
depressed patient’s cognitive disturbances was investigated by Spring et al., (1992), 
by comparing amitriptyline, clovoxamine and placebo in depressed outpatients. Over 
a period of twenty-eight days patients received either placebo (N = 15), amitriptyline 
(N = 10) (50-350  mg/day, mean = 114mg), or clovoxamine fumarate (N= 10) (50 -  
350 mg/day, mean = 138mg). At baseline, and after 7 and 28 days of drug 
administration, memory, psychomotor function, and depression levels were assessed. 
After four weeks of treatment amitriptyline was found to have significantly impaired 
memory as compared to placebo.
The comparative psychopharmacology of 5HT reuptake inhibitors was reported by 
Kerr et al., (1991) using a meta analysis. Studies investigating zimeldine, sertraline, 
paroxetine, fluoxetine, jouveinal, fluvoxamine, amitriptyline and placebo were 
included. All of the studies used comparable psychometric assessment. Amitriptyline 
was reported as having the most significant negative impact on the psychometric tests 
critical flicker fusion and choice reaction time.
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The impact of amitriptyline on cognitive function and psychomotor performance was 
also investigated by Kerr et ah, (1996) in a placebo controlled study comparing 
amitriptyline with reboxetine and alcohol. Volunteers received either 25 mg of 
amitriptyline, 0.5 mg, 1 mg, or 4 mg of reboxetine, or matched placebo with and 
without alcohol, in a double-blind 10-way crossover study. At baseline and after 1, 
2.25, 3.5, 6, and 9 hours post-dose a psychometric test battery was conducted. The 
results demonstrated that amitriptyline with and without alcohol and compared with 
placebo/and or reboxetine had a negative impact on measures of psychomotor 
performance including increased reaction time. Although this research is of interest it 
should be noted that the study was conducted with ten young healthy male volunteers 
and used an acute dosing schedule. It might be that older patients are more susceptible 
to cognitive impairment, or it might be the case that with chronic dosing older patients 
develop a tolerance to the impairing side effects.
In many studies investigating amitriptyline, measures of cognitive function are not 
used but other questionnaires which capture unwanted side effects . Adverse effects 
listed in a profile of amitriptyline by Richelson (1994) include memory dysfunction 
and dizziness. This data adds to the consensus that amitriptyline has behavioural 
toxicity.
Whilst amitriptyline has been studied for its analgesic properties in treating the pain 
associated with painful DPN, the impact on cognitive function in this patient group 
has received limited attention.
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3.2. Duloxetine
Duloxetine is a dual serotonin-noradrenalin reuptake inhibitor (SNRI) which was 
primarily developed as an antidepressant. However early in the development of 
duloxetine it was postulated that this agent would have analgesic properties due to its 
mechanism of action (Leo and Barkin, 2003). These analgesic properties have been 
further investigated in the literature.
Duloxetine is indicated for the treatment of painful DPN, and it was also the first 
agent to achieve regulatory approval for the treatment of painful DPN in the US 
(Smith and Nicholson 2007). In early 2010 the National Institute for Health and 
Clinical (NICE) guidelines for managing painful diabetic neuropathy were updated 
and recommended duloxetine as a first-line treatment for painful DPN, and only if 
duloxetine was contraindicated should amitriptyline be prescribed.
Although the exact mechanisms of duloxetine in relieving the pain associated with 
painful DPN are unknown, these actions are believed to be related to its potentiation 
of serotonergic and noradrenergic activity in the central nervous system and inhibition 
of ascending pathways (Bellingham and Peng, 2010).
As with all drugs, some patients experience unwanted side effects when taking 
duloxetine, the most common of these are nausea, dry mouth, somnolence, fatigue, 
constipation, decreased appetite, and hyperhidrosis.
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3.2.1. Duloxetine as a treatment for painful DPN
Goldstein et al., (2005) investigated the efficacy of duloxetine in patients with painful 
DPN. A total of 457 patients received either 20mg, 60mg, or 120mg of duloxetine 
daily for 12 weeks. The primary efficacy measurement was a weekly mean pain score, 
measured on a Likert scale from 0 -1 0 . Patients receiving 60mg or 120mg of 
duloxetine had a significantly lower pain score as compared with placebo, and this 
continued throughout the study. Similar studies also reported that duloxetine was 
superior to placebo in treating pain in patients with painful DPN (Raskin, Pritchett et 
al. 2005; Wernicke, Pritchett et al. 2006).
Considering that painful DPN is a chronic condition, long-term management is key in 
treating these patients, and any drug used needs to be suitable for long-term use. 
Wernicke et al., (2007) conducted a 52-week open-label extension period on a study 
investigating the use of duloxetine in patients with painful DPN. Patients were re­
randomised to either receive 60 mg duloxetine BID (N=I97) or routine care (N=96). 
The authors concluded that duloxetine is suitable for long-term pain management in 
these patients. Raskin et al., (2006) also reported on an extended investigation into 
duloxetine and concluded that duloxetine was well tolerated compared to routine care 
in the long-term management of patients with painful DPN.
Analgesics for chronic pain conditions also need to be suitable for older patients. 
Wasan et al., (2009) performed a post-hoc analysis on data collected in previous 
duloxetine studies (Goldstein, Lu et al. 2005; Raskin, Pritchett et al. 2005; Wernicke, 
Pritchett et al. 2006). Data was stratified by age, <65 and > 65 years. They reported 
that a significant amount of older patients discontinued treatment due to treatment- 
emergent adverse events (TEAEs) as compared to younger patients. This occurred in
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all the treatment groups including placebo. From this analysis, they concluded that 
there are differences between older and younger patients with regard to medication 
side effects, but duloxetine was generally well tolerated and may be a suitable option 
for older patients who are unable to tolerate other treatment for painful DPN.
3.2.2. Cognitive function and duloxetine
As with all drugs, it’s important to assess if there is any impact of the drug on the 
patient’s cognitive function.
The efficacy of duloxetine on cognition, depression, and pain was investigated in 
elderly patients with major depressive disorder (Raskin et al., 2007). Over a period of 
eight weeks, 60mg of duloxetine per day was compared to placebo(duloxetine N = 
207; placebo N = 104). Cognition was assessed using four tests, the Verbal Learning 
and Recall Test, the Symbol Digit Substitution Test, the Two-Digit Cancellation Test, 
and the Letter-Number Sequencing Test. These four tests were then combined into a 
composite score of cognitive function which was evaluated as the primary outcome 
for this study. Duloxetine was found to significantly improve cognition as measured 
by the composite score, over a period of eight weeks, as compared to placebo.
Duloxetine was also compared with escitalopram in patients with major depressive 
disorder (Herrera-Guzman et al., 2009). In this twenty-four week study patients 
received either 60mg/day duloxetine (N = 36) or lOmg/day escitalopram (N = 37). A 
neuropsychological battery of tests was conducted at the start, and again at the end of 
the study and included measures of working memory, verbal learning and memory, 
visual learning and memory, visuospatial memory, and mental and motor processing 
speed. The authors concluded that both drugs significantly improved aspects of
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memory and mental processing speed in this patient group over the twenty-four week 
period, with duloxetine showing a superior effect in improving episodic memory.
Whilst previous research has indicated that duloxetine improves aspects of cognitive 
function in patients with major depressive disorder, there is very little research on 
duloxetine and cognitive function in patients with painful DPN.
3.3. Pregabalin
Pregabalin is an anti-epileptic drug (AED) which is also indicated for the management 
of pain in painful DPN.
The anticonvulsant action of pregabalin is mediated via enhancement of the inhibitory 
neurotransmitter gamma-amino-butyric acid (GAB A). The mechanism of pregabalin’s 
analgesic action in painful DPN is unclear, but it may reduce excitatory 
neurotransmitter release by binding to the «2-8 protein subunit of voltage-gated 
calcium channels (Dooley et al., 2002; Fink et al., 2002; Luo et al., 2001).
Pregabalin may also cause side effects (Finnerup et al., 2007), some of which are 
likely to be GABA-related. The most common of these are dizziness, somnolence, dry 
mouth, edema, blurred vision, weight gain and abnormal thinking (primarily difficulty 
with concentration/attention).
3.3.1. Pregabalin as a treatment for painful DPN
Rosenstock et al., (2004) investigated the efficacy of pregabalin in treating painful 
DPN compared with placebo. 146 patients received 300mg pregabalin daily for 8 
weeks. The primary efficacy measure was a mean pain score on a 0-10 scale (0 = no
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pain and 10 = worst possible pain). They reported that 300mg pregabalin produced 
significantly lower pain scores as compared with placebo.
A multicentre double-blind placebo controlled study was conducted to investigate the 
use of pregabalin in reducing pain in patients with painful DPN (Tolle, Freynhagen et 
al. 2008). There were four treatment groups, placebo, 150, 300, or 600mg pregabalin 
per day, which were all administered via twice daily dosing. Pain scores were 
measured using an 11-point numerical rating scale as reported in the previous 
pregabalin study. Secondary measures included the EuroQoL Health Utilities Index 
(EQ-5D). A total of 396 patients were randomized, with 395 receiving at least one 
dose of study medication. Pregabalin was found to be superior to placebo in treating 
pain but only at the 600mg dose. The study was conducted over a period of 12 weeks, 
and 600mg of pregabalin achieved a significant reduction in pain by week 2 which 
continued until the end of the study. All dosages significantly improved the EQ-5D 
Utility scores, which indicates improved health-related QoL.
Richter et al., (2005) also investigated the efficacy of pregabalin in the treatment of 
painful DPN. In this multi-centre study 246 volunteers received either 150mg 
pregabalin, 600mg pregabalin or placebo over a period of 6 weeks. 600mg pregabalin 
significantly reduced pain as compared to placebo, whereas I50mg showed no real 
difference. Pregabalin at 600mg also reduced sleep interference and bodily pain scores.
3.3.2. Cognitive function and pregabalin
As with amitriptyline and duloxetine, if  s important to acknowledge whether 
pregabalin has any affect on cognitive function.
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A study investigating the cognitive effects of pregabalin in healthy volunteers was 
conducted over a period of 12 weeks, with the dosage of pregabalin titrated up to 600 
mg/d (Salinksy et ak, 2010). Thirty-two volunteers were randomised to either 
placebo or pregabalin, and cognitive function was assessed at baseline and at the end 
of the 12 week study period. As well as cognitive assessment, the Portland 
Neurotoxicity Scale was used, this is a survey which measures the subjective 
complaints associated with the toxicity of drugs, in particular antiepileptic drugs such 
as pregabalin. Half of the key cognitive measures used were significantly negatively 
affected by pregabalin when looking at test-retest differences between the pregabalin 
and placebo groups. These negative effects were also observed in the Portland 
Neurotoxicity Scale. The authors conclude that pregabalin had a mild negative impact 
on measures of cognitive function, and that this impact should be considered when 
prescribing pregabalin for a chronic condition.
There is little research on whether pregabalin has an effect on cognitive function, 
especially in patients with painful DPN. Previous research on other antiepileptic drugs 
(AEDs) has suggested that AEDs can affect cognition by suppressing neuronal 
excitability or enhancing inhibitory neurotransmission but these effects are fairly 
modest (Ortinski, 2004). Meador (2002), wrote a report about AEDs and their 
cognitive effects in regards to epilepsy. The author lists the cognitive effects of AEDs 
as: impaired attention, vigilance and psychomotor speed, with possible secondary 
effects on other cognitive functions. Elderly patients are also listed as a group which 
are more susceptible to cognitive impairment through the use of AEDs.
Pregabalin is similar in structure to gabapentin and has a similar mechanism of action, 
it would therefore be expected that pregabalin would have a similar cognitive profile 
to gabapentin.
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In a cross-over study, gabapentin was compared with carbamazepine (an older AED) 
by Meador et ah, (1999). There were two five week treatment periods where 35 
healthy volunteers received either 2400 mg/day of gabapentin or a mean dose of 
731 mg/day of carbamazepine. Neuropsychological testing was also conducted, which 
included measures of attention/vigilance, cognitive and motor speed, and memory.
The results indicate that whilst both drugs had an effect on cognitive function, 
gabapentin produced fewer cognitive side effects than carbamazepine, suggesting that 
the newer AED gabapentin is less behaviourally toxic as compared with an older 
generation AED such as carbamazepine.
Gabapentin was compared with carbamazepine in healthy senior adults (Martin et ah, 
2001). A total of thirty four volunteers were randomised, with 15 completing the study 
(mean age 66.5). There were two five week treatment phases with a four week 
washout period. Volunteers were titrated to either 800 mg/day of carbamazepine or 
2400 mg/day gabapentin. Neuropsychological tests were also completed. Compared 
to the non drug phase of the study, both drugs had mild effects on cognitive function, 
but neither was statistically different to each other when compared to non drug. When 
comparing gabapentin with carbamazepine, a significant difference was only found for 
one of the cognitive variables, in favour of gabapentin. Whilst the cognitive effects of 
both AEDs were modest, gabapentin was better tolerated with a better side effect 
profile as compared to carbamazepine in this study of healthy senior adults.
3.3.3. Summary
Pharmacological relief of the pain associated with painful DPN is tricky to manage 
especially as treatment needs to be suitable for long-term use, patients experiencing 
pain are often on the older side, and drugs can cause unwanted side-effects.
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These three drugs amitriptyline, duloxetine, and pregabalin are all used to try and 
alleviate pain in patients with painful DPN. They are three different drugs with 
differing mechanisms of action with regards to their analgesic effects. Because of 
these differing mechanisms of action and the side effects they can produce, and also 
the different levels/type of impact previously seen on cognitive function in relation to 
these treatments, it is probable that when comparing these three drugs in patients with 
painful DPN there will be a difference in any effects exerted on cognitive function.
3.4. Alternative treatments for painful DPN
Pharmacological treatment isn’t always completely effective and patients will seek 
other treatment such as complementary therapies. In a questionnaire-based study 
Brunelli and Gorson (2004) questioned 180 patients with peripheral neuropathy on 
their use of complementary and alternative medicines (CAM). The most reported 
justification for using CAM was inadequate pain control (32% of respondents). Of 
those using CAM (77 patients), 35% used megavitamins, 30% used acupuncture, 19% 
used massage therapy and 16 % used other therapies. 27% of respondents believed 
that their symptoms had improved after therapy, whereas 11% thought their symptoms 
had actually worsened. One aspect worth noting when looking at the results of this 
questionnaire study is that only 26% (47) of the 180 questioned had peripheral 
neuropathy due to diabetes mellitus and there were no randomised controlled trials.
4. Quality of Life (QoL)
Quality of life (QoL) refers to an individual’s ability to enjoy normal life and their 
standard of living. It is a complex concept which is hard to measure, but measuring a
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person’s QoL is essential when assessing illness and disease in order to have a clear 
understanding of their psychological well-being as well as physical (Miguel, Lopez- 
Gonzalez et al. 2008). Health Related Quality of Life (HRQoL) measurements also 
exist. HRQoL refers to quality of life in relation to an individual’s health, so in the 
case of chronic disease, questionnaires may be utilised that measure QoL, but with 
reference to the illness e.g. a question may ask ‘how much have you had to reduce 
your work-load as a result of your back pain?.’ QoL questionnaires can be used to 
measure differences between patients at a given point in time (discriminative 
instruments) or longitudinal changes (evaluative instruments). QoL measurements can 
provide a single global score (health indices), or produce a number of scores 
representing different dimensions of QoL (health profiles).
QoL is measured using questionnaires such as the Short-form 36 (SF-36), this 
questionnaire assesses eight dimensions of an individual’s health including; general 
health, how everyday activities are affected by pain, and emotional state. The scores 
on these dimensions can be brought together as an overall perspective of a person’s 
health and well-being. The SF-36 is on version 2 and has been well validated 
(Jenkinson, Stewart-Brown et al. 1999).
The WHOQOL-100 was developed by the World Health Organisation (WHO) across
15 countries (Power, Harper et al. 1999). It is comprised of 100 questions, which are
grouped into 24 facets which are further grouped into four domains: physical health,
psychological health, social relationships, and environment. A pilot study was
conducted in Croatia, which assessed 63 type 2 diabetics using the WHOQOL-100
(Pibemik-Okanovic 2001). The patients were split into two groups, one group which
switched from oral medication for type 2 diabetes to insulin injections due to poor
control, and the second group remained on their normal oral diabetic medication. After
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two months there was some improvement in the first group on psychological health 
measures but no change for the second group.
4.1. Quality of life and diabetes
Although the main focus of this thesis research was not diabetes, it is important to 
include that individuals with diabetes may already have a reduced QoL prior to 
developing diabetic complications such as painful DPN.
Brown et al., (2000) assessed QoL through interviewing 292 adults with either type 1 
or type 2 diabetes. Patients were asked how many years they expected to live, and how 
many of these years would they trade to be free of diabetes. Utility value analysis was 
used to analyse the results of the interview, they reported that the average patient was 
willing to trade 12% of his or her remaining life to be free of diabetes. Patients were 
also asked about co-morbidities such as retinopathy, neuropathy, and depression. 
Overall 74% had one or more co-morbidities and there was a significant difference 
between having a co-morbidity and not, as assessed by mean utility values. Patients 
using insulin also reported a poorer QoL as compared to those diabetics not using 
insulin.
4.2. Depression and anxiety associated with diabetes
Diabetes is considered to be one of the most demanding chronic diseases which 
impacts on many aspects of psychological well-being, from complex nutritional 
management to diabetic complications (Fisher, Delamater et al. 1982)
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4.2.1. Depression and diabetes
Anderson et al., (2001) conducted a meta-analysis on studies that have reported the 
prevalence of depression in adults with diabetes. They identified 42 studies, 20 of 
which included a non-diabetic comparison group. They reported that in the controlled 
studies, the odds of depression in subjects with diabetes, was twice that of the subjects 
without diabetes. The results also demonstrated that the prevalence of comorbid 
depression was higher in diabetic women as compared to men in the uncontrolled 
studies. These studies demonstrate the negative impact that DM has on an individual’s 
QoL and also highlight the further impact of co-morbidities such as neuropathy and 
depression.
A survey of 367 patients with either type 1 or type 2 diabetes reported that depressive 
symptom severity is associated with increased costs, decreased adherence to treatment 
regimens, and additional functional impairment in these patients (Ciechanowski,
Katon et al. 2000). They suggest that treatment of depression would alleviate these 
associated problems. Non-adherence to treatment regimens would further impact on 
the progression of diabetes over-time and indicates that there is a circular relationship 
between diabetes and depression. Adding to the complicated relationship between 
diabetes and QoL, is that diabetes and stress may also have a circular relationship, e.g. 
stress may interfere with a patient’s regime, therefore undermining metabolic control, 
or poor control may interfere with general functioning (Fisher, Delamater et al. 1982).
Interestingly there has been the suggestion that depression is a risk factor for type 2
diabetes and there is a bidirectional association between the two. There are depressive
symptoms such as obesity-promoting behaviours such as ‘comfort eating’ which could
then lead on to type 2 diabetes. Golden et al., (2008) conducted a longitudinal study on
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a cohort named ‘The multi-ethnic study of atherosclerosis’. They found that 
individuals with raised depressive symptoms have a moderate risk of developing type 
2 diabetes, although this association was no longer significant once they had adjusted 
for lifestyle factors. Even though this study reports only a modest association, it is of 
interest as a bidirectional relationship between diabetes and depression is plausible.
4.2.2. Anxiety and diabetes
Another factor to consider is anxiety. Collins et al., (2009) carried out a cross-sectional 
survey of 2049 patients with either type 1 or type 2 diabetes, they achieved an overall 
response rate of 71% (n=1456). The Hospital Anxiety and Depression Scale (HADS) 
was used to measure anxiety and depression. They reported that females with type 1 
diabetes had double the prevalence of ‘mild’ anxiety as compared to females with type 
2 diabetes. Male diabetics with type 1 experienced more ‘moderate’ to ‘severe’ 
anxiety as compared to males with type 2. In a univariate analysis, lower HADS 
anxiety scores were found to be significantly associated with older age, structured GP 
care, private medical insurance, and perceiving that their glycaemic control was 
‘about right’. Higher HADS anxiety scores were associated with being female, 
diabetic complications, insulin use, unemployment, smoking, heavy drinking, or being 
an ex-drinker. Logistic regression was also performed on the data and higher HADS 
anxiety scores were associated with diabetic complications, not knowing if glycaemic 
control was within the target range, and poor perceived glycaemic control. They 
concluded that the prevalence of anxiety and depression symptoms in diabetics is more 
than double the estimate for the general population. It is likely that higher levels of 
anxiety will have an impact on QoL.
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Hypoglycaemia can also impact on quality of life, with patients suffering from anxiety 
over potential hypoglycaemic episodes. Davis et al., (2005) surveyed 3200 people with 
diabetes, and gathered data for 861 respondents. Using questionnaire data, it was 
concluded that hypoglycaemia has a negative impact on quality of life in individuals 
with diabetes.
4.3. Quality of life and painful DPN
Diabetes rarely occurs in isolation and this can further complicate QoL and its 
measurement. The diabetic complication under review is diabetic peripheral 
neuropathy (DPN) with particular reference to painful DPN.
There is no question that the existence of pain has a large negative impact on quality 
of life, and painful DPN is known to have a negative impact on QoL (Turk and 
Melzack 2001). Smith and Nicholson (2007) note that painful DPN is of great concern 
due to its large prevalence in diabetics, the limited number of treatments, and its 
impact on QoL. Galer et al., (2000) surveyed 220 patients who had previously 
enquired about clinical trials regarding painful DPN, 105 patients completed and 
returned the surveys. As well as demographic data, they completed the Neuropathic 
Pain Scale (NPS), the modified Brief Pain Inventory (mBPI), and the average, worst, 
and least pain during the past week (on a O-IO scale, with 0 = no pain, and 10 = the 
worst pain imaginable). Patients reported an average pain intensity of 5.75 (on a 0-10 
scale), with 61% reporting that their pain is worse when tired, and 46% said their pain 
was worse when they were stressed. On the BPI over 50% of patients reported that 
their pain substantially interfered (defined by a score of > 5) with the following 
activities: sleep, mobility, normal work, enjoyment of life, recreational activities, and 
social activities. There were significant correlations between mBPI scores and the
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pain intensity average, least, and worst, and all the NPS scores except for itching. This 
data demonstrates that painful DPN has a measurable, negative impact on QoL, as 
measured by pain questionnaires. One limitation of this study is that the patients 
recruited were already seeking to participate in a clinical trial for painful DPN and, 
therefore the results may be biased as patients were motivated by their pain to seek 
treatment.
Benbow et al., (1998) assessed QoL in 3 groups of subjects: 41 diabetics (type 1 and 
2) with DPN, 38 diabetics (type 1 and 2) with no neuropathy, and 37 non-diabetic 
control subjects. QoL was assessed using the Nottingham Health Profile (NHP) which 
assesses six areas: energy, sleep, pain, physical mobility, emotional reactions, and 
social isolation, subjects answer yes or no to 38 statements and scores range from 0- 
100, a score of 100 indicates a presence of all of the limitations listed. As well as the 
NHP, QoL was measured using the McGill pain questionnaire, and the patients with 
DPN completed three visual analogue scales to indicate their pain in the morning, 
before lunch, and late evening. These scores were totalled to produce a mean pain 
score for each patient. The diabetic group with painful DPN had significantly higher 
scores on five of the six domains of the NHP, as compared to the other groups, the 
only one that was not significant was social isolation. The group with diabetes and no 
neuropathy also had significantly higher scores as assessed by the NHP on the 
domains; energy, sleep, pain, and physical mobility, as compared to the non-diabetic 
control group. This study demonstrates that diabetes has a negative impact on QoL as 
assessed by the NHP, and that QoL is further impacted by the presence of diabetic 
peripheral neuropathy. Wee et al., (2005) studied the impact of diabetes and other 
chronic medical conditions on HRQoL. This was investigated using the SF-36 and the 
SF-6D in a population-based survey of Chinese, Malay, and Indians in Singapore. The
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resulting data indicated that subjects with diabetes have a lower HRQoL as compared 
to subjects without diabetes. The concurrent medical conditions: hypertension, heart 
disease, and musculoskeletal illness, further lowered HRQoL scores in patients with 
diabetes.
QoL is a concept that is becoming increasingly valued in research. As it stands, data 
quantifying the degree to which type 1 and type 2 diabetes, their treatments, 
complications and co-morbidities affect QoL is seriously lacking (Coffey, Brandie et 
al. 2002). Diabetes is on the increase, one prediction suggests that 366 million people 
worldwide will have diabetes by 2030, (Wild et al., 2004). As the prevalence of 
diabetes increases, so will the prevalence of complications unless major breakthroughs 
in their treatment occurs. Society is also ageing, which has led to a considerable 
increase in elderly diabetics and this trend is likely to continue (Bruce, Casey et al. 
2003). Further research is required into DM and its impact on QoL, in particular 
focusing on diabetic complications and QoL.
4.4. Improving Quality of Life in patients with painful Diabetic 
Peripheral Neuropathy
In the open label 52-week extension study, quality of life was assessed along with the 
efficacy of duloxetine on relieving pain in patients with painful DPN (Wernicke, 
Wang et al. 2007). Patients were randomized to either receive duloxetine or routine 
care. There were significant differences between the groups, with duloxetine 
improving the SF-36 physical component summary score, and the subscale scores of 
physical functioning, bodily pain, mental health, and vitality. This suggests that as 
well as being beneficial in reducing pain associated with DPN, duloxetine may also 
improve quality of life ratings.
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Duloxetine is also an anti-depressant so it is likely that it would be beneficial in 
treating depression associated with chronic illness as well as the pain experienced by 
painful DPN patients (Muller, Schennach et al. 2008).
5. Cognitive function
Cognitive function refers to the mental processes employed by individuals on a daily 
basis to carry out activities. These mental processes can be divided into domains such 
as learning, memory, attention, perception, reaction-time, problem-solving, decision­
making. These domains can be measured using computerized or ‘paper and pencil’ 
tests, the results of these tests give an indication of a person’s cognitive ability at that 
point in time.
5.1. Cognitive function and diabetes
The link between cognitive function and diabetes is of great interest to researchers 
from all fields, as it impacts on many aspects of a patient’s life. In an extensive review 
on cognition and diabetes, Kodl and Seaquist (2008), have summarised which 
cognitive domains are negatively affected by diabetes. For type I DM the cognitive 
domains; slowing of information processing, psychomotor efficiency, attention, 
memory, learning, problem solving, vocabulary, general intelligence, 
visuoconstruction, visual perception, motor strength, mental flexibility, and executive 
function are all affected. For type 2 DM they summarised that the following 
cognitive domains are negatively affected; memory, psychomotor speed, executive 
function, processing speed, complex motor function, verbal fluency, and attention.
Brands et al., (2005) conducted a meta-analysis of 33 studies that assessed cognitive 
function in patients with type 1 DM. As compared with nondiabetic controls, type 1
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diabetics had a significantly reduced performance on the measures of: psychomotor 
efficiency, sustained attention, intelligence, visual, speed of information processing, 
visual perception, and cognitive flexibility. Fontbonne et al., (2001) assessed a cohort 
of elderly patients (divided into groups according to glucose levels; normal, impaired 
fasting glucose (IFG), or diabetic) over a 4 year period using the Mini Mental State 
Exam (MMSE) and various measures of cognitive function including digit symbol 
substitution and trail making test B. They concluded that in diabetic subjects, as 
compared to the rest of the elderly patients, cognitive performance declines over four 
years, in particular measures of verbal memory, visual and sustained attention, visuo­
spatial processing, and psychomotor speed were significantly impaired. These results 
demonstrate a link between diabetes and cognitive decline, however, diabetes rarely 
occurs in isolation, and this must be considered when reviewing the literature on 
diabetes and cognitive function.
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5.2. Cognitive function and chronic pain
Cognitive 
function & 
chronic pain
Cognitive dysfunction the result 
of pain or the neurological 
disorder that is causing the pain?
Cognitive impairment a product of 
pain, or the emotional distress caused 
by the pain?
Cognitive impairment as a 
consequence of pain, or the 
pain treatment having a 
negative impact e.g. 
opioids?
Figure 1 A figure displaying the complex relationship between cognitive function and chronic 
pain
The relationship between cognitive function and chronic pain is extremely complex, 
with various concerns to take into consideration when looking at cognitive function in 
individuals with chronic pain. Figure 1 illustrates the possible associations between 
cognitive function and chronic pain.
Firstly in patients with a neurological based illness, there is the question of whether it 
is the pain impacting on cognitive function, or the neurological disorder which is 
causing the pain but also affecting cognition.
Then there is the issue of pain treatments; opioids often have a negative impact on 
cognitive function, so the issue here is whether it’s the pain having an impact on
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cognition, or the treatment used to alleviate the pain (Zacny 1995; Chapman, Byas- 
Smith et al. 2002; Argoff and Silvershein 2009).
Emotional distress is often present in individuals with chronic pain which further 
complicates the relationship between pain and cognitive function (Hart, Wade et al. 
2003). Anxiety, depression, stress, or a combination of these can all affect cognitive 
function directly, or indirectly via fatigue and disordered sleep.
It would seem probable that pain has an impact on cognitive function, due to its 
demanding nature (Eccleston and Crombez 1999). However with chronic pain it is 
also likely that individuals have learnt to cope with their pain and it may not be as 
distracting as acute pain. Sjogren et al., (2005) assessed patients with non-malignant 
pain at the multidisciplinary pain centre. There was a total of 91 patients in the painful 
group, and 64 in an age and gender matched control group. The patients were further 
divided into 4 sub-groups. Group 1 received no pain medications (n=21). Group 2 
were in long-term treatment with opioids (n= 19), Group 3 were treated with 
antidepressants and/or anticonvulsants (n=18), whilst Group 4 were treated with a 
combination of the treatments used in the previous groups, i.e. antidepressants and 
long-term opioid treatment. Assessments included a VAS for measuring pain (PYAS), 
a VAS for measuring sedation (SVAS) and the Mini Mental State Examination 
(MMSE). Neuropsychological assessments included Continuous Reaction Time 
(CRT), Finger Tapping Test (FTT), and a Paced Auditory Serial Addition Task 
(PAS AT). The authors concluded that this population of non-malignant pain patients 
demonstrated reduced sustained attention and slower psychomotor speed as compared 
to a healthy control group.
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5.3. Cognitive function/psychomotor function and painful DPN
Diabetic Peripheral Neuropathy (DPN) has been indicated as a cause of cognitive 
impairment, with psychomotor efficiency being the most significantly affected. Ryan 
et ah, (1992) administered a battery of neuropsychological tests to 75 diabetic adults,
42 of whom were diagnosed with neuropathy. They reported that neuropathy adversely 
affected psychomotor efficiency. Ryan (2005) assessed problem-solving, learning and 
memory, and psychomotor efficiency in 200 adults with type 1 DM and 175 non­
diabetics. Psychomotor efficiency was significantly reduced in the diabetic subjects 
when compared to the control subjects. The author goes on to list DPN as a predictor 
of psychomotor slowing.
The relationship between diabetes, cognitive function, and peripheral neuropathy 
remains controversial (Brismar et al. 2007). Brismar et al (2007) investigated possible 
predictors of cognitive impairment in patients with type 1 diabetes.
Neuropsychological assessment included tests of picture completion, Rey Complex 
Figure Test (RCFT), Trail Making Test Part B (TMT B), Paced Auditory Serial 
Attention Test (PASAT), Grooved Pegboard Test, Controlled Oral Word Association, 
Zoo Map Test, and Claeson -  Dahl’s test of learning and memory. Peripheral 
neuropathy was measured using a neurological impairment assessment (NIA) tool.
The authors identified the predictors of cognitive impairment with, long diabetes 
duration, young age at diabetes onset and presence of peripheral nerve conduction 
defects having the strongest correlation with impairment. The least affected was verbal 
ability whilst psychomotor speed and visual perception-organization showed the 
strongest dependency on any of the disease variables. In particular, there was an 
association between psychomotor slowing and neuropathy.
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Although psychological well being was not evaluated in the study, they note that a 
relatively high percentage (10%) of the patients was on anti-depressive medication in 
comparison to overall use, this ties in with earlier discussions on diabetes and co­
morbid depression.
5.4. Cognitive function and glycaemic control
Hypoglycaemia impairs cognitive function in patients with type 1 DM. Langan et ah, 
(1991) examined 100 patients with type 1 DM, including a questionnaire on frequency 
of hypoglycaemia and a detailed neuropsychological assessment which included IQ, 
memory and information-processing speed. Significant correlations were observed 
between the frequency of hypoglycaemia and reaction time, inspection time, and 
Performance IQ. Deary et ah, (1992) recalled 85 of the 100 patients from the Langan 
et ah, (I99I) study and tested their IQ along with the Hick Reaction Time task, the 
Sternberg Memory Scan task, and a test of Rapid Visual Information Processing 
(RVIP). As before, frequeney of hypoglycaemia was also recorded. Their results 
showed a significant correlation between frequency of hypoglycaemia and Hick 
decision times and response times in the RVIP task. In a study by Draelos et ah, (1995) 
they found that cognitive function was diminished by hypoglycaemia (in this study 
defined as 2.2 mmol/L), in particular, associative learning, attention, and mental 
flexibility. This was assessed in 42 patients with type 1 DM using tests of sensory 
perceptual processing, motor abilities, attention, learning and memory, language, and 
spatial and constructional abilities. These tests were performed at various levels of 
plasma glucose, ranging from 2.2 mmol/L to 21.1 mmol/L. In addition Ewing et ah, 
(1998) reported that hypoglycaemia significantly impairs visual information 
processing and general cognitive ability in adults with type 1 DM. They assessed 16 
adults with type 1 DM, using tests of visual processing and cognitive function, whilst
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using a hyperinsulinémie glucose clamp to maintain blood glucose levels. Patients 
were assessed at blood glucose levels 2.6 mmol/L (hypoglycaemia) and 5.0 mmol/L. 
Although hypoglycaemic episodes may reduce cognitive performance, hypoglycaemic 
unawareness may also further impact on cognitive fimction. Goldstein et ah, (2005) 
examined the degree of cognitive dysfunction experienced by patients with impaired 
hypoglycaemia awareness as compared with patients with normal awareness of 
hypoglycaemia. Cognitive function was assessed in 10 patients with normal awareness, 
and 10 patients with a history of impaired hypoglycaemia awareness. The patients 
were allocated into groups according to their response on a visual analogue scale 
which assessed awareness of hypoglycaemia, with 1 = always aware and 7 = never 
aware, patients that scored 4 or more were categorized as having impaired awareness. 
The assessments used were: RVIP, Trail Making B (TMB), Paced Auditory Serial 
Addition Test (PASAT), and Digit Symbol Substitution Test (DSST). In keeping with 
previously reported studies, hypoglycaemia had a significant impact on cognitive 
function. As well as hypoglycaemia impacting on cognitive function, subjects with 
impaired awareness had more false positive responses (misses) as assessed by RVIP. 
They also reported that for the patients with impaired awareness, their cognitive 
dysfunction persisted for longer period of time than the subjects with normal 
awareness on recovery from hypoglycaemia. Therefore, as well as hypoglycaemia 
effecting cognitive function, these results indicate that this dysfunction is more long- 
lasting in individuals with impaired awareness of hypoglycaemia.
Whilst current hypoglycaemia appears to impact on cognitive function, Brismar et al., 
(2007) reported that a history of frequent hypoglycaemic events did not predict 
cognitive dysfunction, however they did find that early age onset of diabetes was a 
predictor of cognitive decline so cannot rule out the effect of hypoglycaemic events.
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Hyperglycaemia has also been reported to negatively impact on cognitive function.
Cox et ah, (2005) examined the effect of hyperglycaemia on cognitive function in 
adults with type 1 and type 2 DM. The study was divided into 3 groups with 105 
patients with type 1 DM in group 1, 36 patients with type 2 DM in group 2, and 91 
adults with type 1 DM in group 3. The patients completed cognitive tasks on a hand­
held computer, then measured and entered their blood glucose level. This was done 70 
times over 4 weeks. Hyperglycaemia (>15 mmol/L) was associated with cognitive 
slowing on all performance measures. Sommerfield et al. (2004) assessed the impact 
of hyperglycaemia on cognitive function in 20 adults with type 2 DM. Cognitive 
function was measured using tests of information processing, immediate and delayed 
memory, working memory, and attention. They reported that hyperglycaemia (16.5 
mmol/L) had a negative impact on speed of information processing, working memory 
and aspects of attention. In contrast, some studies have suggested that hyperglycaemia 
has no significant impact on cognitive function. Draelos et ah, (1995) examined 
cognitive function using tests of vigilance, reaction time, and memory, during 
hyperglycaemia and hypoglycaemia, in 42 patients with type 1 DM (see above). They 
concluded that cognitive function is not impaired during hyperglycaemia (cognitive 
tests conducted at 14.4 mmol/L and 21.1 mmol/L). Gschwend et ah, (1995) also 
concluded that hyperglycaemia (defined as 20 mmol/L) does not significantly affect 
cognitive function. Cognitive function was assessed in 36 children (9-19 years of age) 
with type 1 DM, using measures of simple reaction time, choice reaction time, and 
trail making.
There is a clear divergence in the literature as to whether hyperglycaemia does or does 
not impair cognitive function.
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Although hypoglycaemia, hyperglycaemia, and micro-vascular complications such as 
neuropathy have been linked with cognitive decline/impairment in type 1 and type 2 
diabetes, the causes behind cognitive dysfunction remain controversial (Cleeland and 
Ryan 1994). Fontbonne et ah, (2001) caution that conclusions regarding cognitive 
decline and diabetes are hard to reach as comparisons often suffer from 
methodological problems e.g., small samples, varying levels of blood glucose, 
different tests and different areas of cognitive function assessed, and failure to 
control for major confounding factors such as age and education.
As the prevalence of diabetes, and therefore it’s complications, is continually rising, 
further research into the impact of diabetes on cognitive function is required. In 
addition, there has been little research into the impact of painful DPN on cognitive 
function. Painful DPN is a serious complication of diabetes and further research is 
required into the impact is has on patient’s lives. Future research needs to take into 
account the various causes of dysfunction when analyzing results.
5.5. Cognitive function and pharmacological treatment
Assessing cognitive function in relation to pharmacological treatment is of great 
importance, as a drug may be beneficial to the patient i.e. relieving pain, but if this 
comes at the expense of memory or other cognitive abilities, then the treatment is 
countertherapeutic and an alternative should be considered. This impact on cognitive 
function (including psychomotor function) is also referred to as ‘behavioural toxicity’. 
Measuring behavioural toxicity is a valuable component of psychopharmacological 
research as a drug which is detrimental is considered to be behaviourally toxic, but a 
drug that is also over-stimulating is also considered to be behaviourally toxic. 
Therefore when developing new medicines, the aim is to find a pharmacological
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solution which is behaviourally neutral. With chronic conditions such as painful DPN 
a drug needs to provide daily pain relief, without impacting on everyday function, on 
a long term basis. An extra complication in drug selection, is the fact that patients 
with painful DPN tend to be older adults and therefore any drug used needs to be 
appropriate for use in the elderly.
6. Sleep
Sleep is essential to our existence and every-day life (Van Dongen and Dinges 2005). 
Sleep can be measured using subjective questionnaires, actigraphy, or 
polysomnography or a combination of these measures (Cirelli and Tononi 2008; 
Krystal and Edinger 2008).
6.1. Sleep disturbed by pain
The relationship between sleep and pain is complex. Chiu et al., (2005) examined 424 
participants to determine if sleep disturbance affects an individual’s pain threshold. 
This was assessed through questionnaires and the Fischer Pressure Algometer was 
used to measure pain threshold. They concluded that disturbed sleep is associated with 
a lower pain threshold. Morin et al., (1998) reported that disturbed sleep is a prevalent 
complaint in patients with chronic pain, as assessed by self-reported measures of sleep 
and pain in 105 patients. Menefee et al., (2000) conducted a review of the literature 
concerning sleep disturbance and non-malignant chronic pain. They reported 
consistent findings of chronic pain significantly disturbing sleep. However, the 
relationship between pain and sleep is complicated by the limitations of self-report 
measures of sleep, and mood disturbances such as depression.
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When considering painful DPN and sleep, it is important to acknowledge that 
nocturnal exacerbation of neuropathic symptoms (NENS) is a known symptom of 
DPN. Therefore for individuals suffering from painful symptoms, it is plausible that 
the symptoms will worsen during the night and further impact on sleep quality.
It follows that the pain experienced by patients with painful DPN will disrupt their 
sleep, however the data for this is fairly limited. Gore et al., (2005) surveyed 255 
patients with painful DPN. Patients in this study reported significantly greater sleep 
impairment when compared to the general U.S. population, and all aspects of sleep 
were affected as measured by the Medical Outcomes Study (MGS). These results are 
limited by the fact that the sleep problems are self-reported, a more accurate 
measurement of sleep disturbance in this population would be polysomnography.
Further research is required to attain a complete picture of the complex, circular 
relationship between pain and sleep, with particular reference to painful DPN.
7. Aims of thesis
The primary objective of this thesis research was to compare the effects of three drugs 
used to relieve pain associated with painful DPN, amitriptyline, duloxetine, and 
pregabalin. As these three drugs belong to different categories of drugs and have 
distinct modes of action, there was a particular focus on their effects on cognitive 
function as well as their pain relieving properties in this patient group. This 
comparison of these three drugs was conducted under controlled conditions with 
patients reporting pain associated with painful DPN.
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The secondary objective of this thesis research was to investigate correlations 
between subjective symptoms (including quality of life) at baseline and after 
pharmacological treatment.
Based on previous research this thesis investigated the hypotheses that:
• One or more of the drugs will be superior in relieving pain
• The effect of each drug on cognitive function will differ in accordance with 
their modes of action in the central nervous system
• With reduced pain scores, Quality of Life scores will increase
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Chapter 2: Methods
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8. Methods
The thesis research was a parallel design study in patients with painful DPN, to 
investigate pain relieving properties, along with impact on cognitive function and 
quality of life, of three drugs which are either licensed for treating pain associated 
with painful diabetic peripheral neuropathy (DPN), or recommended by the British 
national formulary (BNF). The drugs investigated were pregabalin, duloxetine, and 
amitriptyline.
8.1. Patients
Diabetic patients with either type 1 or type 2 diabetes were recruited from The Royal 
Bournemouth Hospital and Poole Hospital. They had to have been diabetic for at least 
1 year and have neuropathic pain of diabetic origin, assessed by a score of 12 or above 
on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) (Bennett 
2001). They were also required to achieve a score above 25 on the Mini Mental State 
Exam (MMSE) (Appendix 1) (Folstein et al., 1975). This was used to ensure the 
patients had a suitable level of cognitive function to complete the cognitive tests.
They also had to be willing to withdraw from current pain medication under the 
guidance of their diabetologist. Patients were excluded if there was any evidence of an 
end stage disease of a major system, recent ischemic event, or severe hypoglycaemia 
in the last 3 years. They were also excluded if under treatment for malignancy, 
suffered from seizures, had a dependency on alcohol/recreational drugs, had 
participated in a clinical trial in the previous 3 months or had vision that was 
inadequate for the performance tests. Patients with colour-blindness were included but
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data was excluded from analysis where appropriate. All patients gave written informed 
consent before any procedures were performed. This study was conducted with ethical 
approval and under Good Clinical Practice (GCP) guidelines.
8.2. Study Design
The study followed a double blind, parallel groups design with three treatment arms. 
The treatments used were amitriptyline, pregabalin, and duloxetine. From Day 1 to 8 
volunteers were instructed to take single blind placebo caplets, two in the morning, 
and two in the evening. From the evening of Day 8 to Day 22 patients received either 
pregabalin 150mg bd (twice daily), duloxetine 60mg on (every night), or 
amitriptyline 25mg bd. From Day 22 the dose was increased to pregabalin 300mg bd, 
duloxetine 60mg bd, or amitriptyline 25mg om (every morning) and 50mg om, the 
drugs were encapsulated and re-packaged to ensure that study personnel and patients 
were blind to the nature of the medications. See Figure 2 for dosing schedule. Patients 
were in the clinical phase of the trial for a total of 36 days. During the study they were 
resident at the Surrey clinical research centre from day 6-8, 20-22, and 34-36. After 
completing the clinical phase of the study, the patients then attended a follow up 
session at their diabetic clinic.
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Single-blind 
placebo run-in 
Day 1-8
600mg 
Pregabalin Day 
22-36
120mg 
Duloxetine 
Day 22-36
60mg 
Duloxetine 
Day 8-22
75mg 
Amitriptyline 
Day 22-36
50mg 
Amitriptyline 
Day 8 - 22
300mg 
Pregabalin 
Day 8-22
Figure 2: Dosing schedule for the study
Dosing
Sleep electrodes attached for 
overnight PSG recording
Subjects arrive at Surrey 
CRC approx 17:00
Once settled continuous glucose 
monitor attached (MINIMED)
Day 6/20/34
Dinner was provided
(snacks and drinks available 
throughout the residential 
period as required)
Subjects went to bed in their 
individual, sound attenuated, 
light-controlled sleep rooms, 
electrodes were checked and 
lights out was at 23:00
Figure 3 Subject schedule for Day 6/20/34
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Dosing
Lunch was provided
Dinner was provided
Sleep electrodes attached for 
overnight PSG recording
Free time with drinks and 
snacks provided
Subjects went to bed in their 
individual, sound attenuated, 
light-controlled sleep rooms, 
electrodes were checked and 
lights out was at 23:00
Glucose levels checked through 
the day as required, as well as 
continuous measurement with 
CGMS monitor
Day 7/21/35
First training session on the 
cognitive testing on day 7, for day 
21 and 35 this was a re­
familiarisation session with the 
cognitive testing
10:00
Second training session on the 
cognitive testing on day 7, for day 
21 and 35 this was a re­
familiarisation session with the 
cognitive testing
13:00
Third training session on the 
cognitive testing on day 7, for day 
21 and 35 this was a re­
familiarisation session with the 
cognitive testing
16:00
Subjects were woken up and 
sleep electrodes removed 
Breakfast was provided and 
patients given the opportunity 
to shower
07:00
Dosing and diary completion
09:00
Figure 4 Subject schedule for Day 7/21/35
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Lunch was provided
Glucose monitors were 
removed
Free time with drinks and 
snacks provided
Dosing and diary completion
09:00
First cognitive testing session o f 
the day
08:00
07:00
Subjects were woken up and 
sleep electrodes removed
Fourth and final cognitive testing 
session o f  the day
16:00
Third cognitive testing session o f 
the day
13:00
Second cognitive testing session 
o f  the day
10:00
From day 2 - 5 , 9 - 1 9 ,  and 23 -  
33, subjects were telephoned 
daily to ensure IMP compliance 
and record any adverse events
Day 8/22/36
Glucose levels checked through 
the day as required, as well as 
continuous measurement with 
CGMS monitor
Patients were discharged from 
Surrey CRC with diaries, 
blinded investigational drug 
(IMP)and instructions on 
dosing
On day 36 all diaries and empty 
IMP packets collected, patients 
were discharged from the Unit 
and asked to attend a follow up
Figure 5 Subject schedule for Day 8/22/36
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8.2.1. Measurements
Assessment schedule
Screening assessments 
include d SF-36v2, 
LANSS & BPI
AI
I
I
Patient diary started 
on Day 1 and 
completed every 
day for the duration 
of the study
08
GTE and other tests 
completed at 08:00,10:00, 
13:00 & 16:00
I
I
i
ÀIII
0 7  Training on the 
GTE and other tests 
completed at 10:00, 
13:00, & 16:00
022
GTE and other tests 
completed at 08:00, 
10:00,13:00 & 16:00
I
I
t
À
I
I
I
021 Re-familiarisation on 
the GTE and other tests 
completed at 10:00,13:00, & 
16:00
036
GTE and other tests 
completed at 08:00,
10:00,13:00 & 16:00
, SF-36v2
• completed
^  again on
r ^  036
À
I
I
I
035  Re-familiarisation on 
the GTE and other tests 
completed at 10:00,13:00, 
& 16:00
Figure 6 Assessment schedule fo r the  study 
8.2.2. Pain measurements
Part of the primary objective of this thesis research was to compare the pain relieving 
properties of amitriptyline, duloxetine, and pregabalin. In line with previous research 
outlined earlier in this thesis (Dallocchio et ah, 2000; Goldstein et ah, 2005; Morello 
et ah, 1999 ; Raskin et ah, 2005; Richter et ah, 2005; Rosenstock et ah, 2004; Tolle et 
ah, 2008; Wernicke et ah, 2006) the following pain measurements were used.
8.2.2.I. The Visual Analogue Scale (VAS)
Throughout the study the patients completed a diary on a daily basis which included a 
sleep questionnaire, the Brief Pain Inventory (short form) (BPI), and a Visual 
Analogue Scale (VAS) (see Figure 7). The VAS used was taken from the Short Form 
McGill Pain Questionnaire (Melzack 1987). Patients were asked to rate their pain on a 
100mm line scale, with the left end equalling no pain, and the right end worst possible 
pain.
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Visual Analogue Scale
Please indicate on this line how bad your pain is - 
at all, at right end means worst pain possible. Plee 
marker e.g.
- at the left end o f  line means no pain 
ise use a single vertical line as a
Worst
No
pain
possible
pain
Figure 7: Visual Analogue Scale (VAS).
This VAS was taken from the Short Form McGill Pain Questionnaire and measured self- 
reported pain from no pain to worst possible pain, the scale was measured with a ruler and a 
score from 0 -100mm was recorded.
8.2.2.2. The Brief Pain Inventory
The Brief Pain Inventory (BPI) is a numerical rating scale (NRS) which was 
originally designed to measure cancer pain (Cleeland and Ryan 1994) (See Appendix 
3). It assesses pain over a 24hr period asking patients to rate their pain on a series of 
questions from 0 -1 0 . There are 4 questions relating to pain severity including worst 
pain, least pain, average pain and current pain where 0 represents ‘no pain, whereas 
10 equals ‘pain as bad as you can imagine’. These questions are combined to make a 
pain severity score (BPI pain severity). In addition there are 7 questions regarding the 
impact of pain on activities such as sleep, walking and enjoyment of life, and for these 
questions 0 represents ‘does not interfere’ and 10 is ‘interferes completely’. The 7 
questions are combined to make a pain interference score (BPI pain interference). 
Individual and combined scores can be used to assess pain change.
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The BPI has also been validated for chronic non-malignant pain Tan et ah, (2004), 
and has been used to measure pain in previous studies in patients with painful DPN 
(Galeret ah 2000, Goldstein et ah 2005; Raskin et ah 2005)
8.3. Cognitive Assessment
In order to evaluate any potential side effects of the drugs on cognitive function (one 
of the primary objectives of this thesis research), a comprehensive battery of 
neuropsychological tests was employed. The battery of psychometric tests was 
selected to cover a range of cognitive domains including memory, psychomotor 
function, attention, and reaction time. The psychometric measures were also selected 
based on previous research investigating cognitive function and the three study drugs 
(Herrera-Guzman et ah, 2009; Kerr et ah, 1991; Kerr et ah, 1996; Martin et ah, 2001; 
Meador et ah, 1999; Meador, 2002; Raskin et ah, 2007; Salinsky et ah, 2010; Spring et 
ah, 1992). The aim was to use a comprehensive selection of tests without ‘over-testing’ 
this group of patients. These tests have all been well validated and previously used in 
clinical trials.
Cognitive function was assessed 4 times a day (at 08:00, 10:00, 13:00, and 16:00) 
during residential periods of the study. As well as this the patients were first trained on 
how to complete the psychometric tests. At the start of the second two residential 
periods, the patients were re-familiarised with the cognitive tests. The training and re­
familiarisation aimed to reduce the confounding variable of ‘leaming-effect’ to ensure 
that the data collected was as accurate as possible.
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Cognitive and psychomotor function was assessed using a battery of psychometric 
tests. These were predominantly computerised (the computerised tests used were part 
of the Guildford Test Battery, GTB) but some were paper-based. The tests included 
the Karolinska Sleepiness Scale (KSS), Visual Analogue Scale measuring pain (VAS), 
immediate and delayed recall of words. Digit Symbol Substitution Task (DSST),
Stroop task, Short-Term Memory task (STM), Continuous Tracking Task (CTT), 
Critical Flicker Fusion (CFF), and Choice Reaction Time (CRT). The 
tests/measurements used are grouped by category and described further below:
8.3.1. Learning and Memory
8.3.I.I. Immediate and Delayed Recall of Supraspan Words (Wri 
and WRd)
Immediate recall is thought to involve the central executive component of working 
memory, whilst delayed recall is assumed to be a measure of explicit memory 
(Baddeley and Hitch 1974; Baddeley 1986). Each word list consisted of 20 nouns and 
subjects were given 2 minutes exposure and learning time to read and memorise each 
list, immediately followed by a two minute period in which they wrote down as many 
of the words as they could recall (WRi). After approximately 30 minutes had elapsed 
(from the learning period) subjects were given a further two minutes to write down as 
many words as they could recall (WRd). The WRi and WRd scores were calculated as 
the number of words recalled correctly.
8.3.12. Short Term Memory Task (STM)
STM is a task that assesses short-term memory, in particular high-speed scanning of 
memory, and reaction time (Sternberg, 1966). Subjects memorised a set of letters in a 
sequence of 2, 4, or 6 and were then presented with a single white letter. Subjects then
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indicated whether the white letter was in the set by pressing the appropriate response 
button (green button for yes, red button for no) as quickly, yet as accurately as 
possible. The responses were measured in reaction-time for valid responses.
8.3.2. CNS arousal and information processing
8.3.2.1. Digit Symbol Substitution Test (DSST)
The DSST, Wechsler (1981), is a pen and paper test which consists of rows of blank 
squares paired with randomly assigned digits (between 0 and 9). Subjects were 
required to substitute each digit with a different nonsense symbol, according to a key 
printed at the top of the sheet which indicates the nonsense symbol that corresponds to 
each digit. Subjects were given 90 seconds to substitute as many digits with symbols 
as possible. For repeated testing the symbols in the key were scrambled. The test 
involved the recognition and recoding of sensory information and has been described 
as a measure of information processing and of psychomotor performance (Lezak 
1995).
8.3.2.2. Stroop task
The Stroop task can be presented in either alpha or numeric mode; for the Guildford 
Test Battery it is presented in alpha mode. The words red, blue, green, and yellow 
were presented to the subjects in varying colours (red, blue, green, or yellow).
Subjects then decided if the word and the colour matched, if they did match they 
pressed the green button, and if they didn’t match then they pressed the red button. 
This task assessed the ‘Stroop effect’, Stroop (1935), where the conflicting colour 
presentation interferes with the cognitive process of naming colours resulting in a 
longer reaction time. Responses to this task were measured using the reaction time for 
valid responses.
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S.3.2.3. Critical Flicker Fusion (CFF)
Critical flicker fusion (CFF) is a task which provides an index of central nervous 
system activity, or “cortical arousal” (Hindmarch, 1982). In particular, CFF assesses 
the ability to distinguish between discrete sensory events. A lowering of the threshold 
is indicative of a reduction in the overall integrity of the central nervous system.
Subjects were required to discriminate flicker from fusion, and vice versa, in four 
light emitting diodes (LED’s) arranged in a one-centimetre square on a black 
background. The diodes were held in foveal fixation at a distance of one metre. 
Responses were measured in Hz and the variables recorded were mean threshold 
frequency.
8.3.3. Sensorimotor Co-ordination
8.3 3.1. Continuous Tracking Task (CTT)
The CTT assesses psychomotor function and divided attention. The CTT task 
consisted of a white ball moving horizontally across the computer screen, a green 
crosshair was also present on the computer screen which was controlled by the 
position of the slider on the response box. The subjects were required to track the 
movement of the white ball with the crosshair as closely as possible. At random 
intervals stimuli, in the form of yellow balls, appeared in one of the four comers of 
the screen. The subjects were required to acknowledge this peripheral stimulus by 
depressing either of the response buttons on the response box, whilst simultaneously 
tracking the ball across the computer screen. CTT performance has been shown to be 
sensitive to psychoactive compounds (Hindmarch 1980). Lower tracking error scores 
are indicative of more accurate tracking.
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8.3.4. Psychomotor speed
8.3.4.1. Choice Reaction time (CRT)
The CRT task is used as an indicator of sensorimotor performance, assessing the 
ability to attend and respond to a stimulus. Subjects were required to extinguish 1 of 6 
equidistant red lights, illuminated at random, by pressing the associated response 
button as quickly as possible. Mean response measures of 60 trials were recorded in 
milliseconds. Three components (recognition time, motor time and total reaction time) 
were recorded. Recognition time was measured from stimulus onset to the subject 
lifting their finger from the start button, and motor reaction time was measured from 
lifting the finger from the start button to touching the response button. Total reaction 
time was the sum of these two measures. CRT has been shown to be sensitive to the 
effects of psychotropic drugs (Hindmarch 1980).
8.3.5. Subjective ratings
8.3.5.1. Karolinska Sleepiness Scale (KSS)
Participants were shown a nine-point scale and asked to choose a number between 1 
(very alert) and 9 (very sleepy, great effort to keep awake) to reflect the level of 
sleepiness they were currently feeling (Gillberg, Kecklund et al. 1994).
8.3.5.2. Quality of Life
The patients completed the SF-36 version 2 at screening and again on day 36 in order 
to assess any changes in their QoL from baseline and after treatment (as part of the 
secondary objectives of this thesis research). The SF-36 is a short-form health survey 
which assesses quality of life and produces eight component scores, a physical 
component summary score, and a mental health component summary score.
66
(Jenkinson, Stewart-Brown et al. 1999) The SF-36 was selected for use in this thesis 
research based on previous use in similar studies and with the drugs under 
investigation (Armstrong et al., 2007; Rosenstock et al., 2004; Swislocki et al., 2009; 
York and Gordon 2009).
(See Appendix 2).
9. Statistical analysis
Due to a lack of relevant information to enable powering of pairwise comparisons of 
the three treatments, a formal power calculation could not be conducted. However 
information was available on before and after treatment with duloxetine from 
previous studies (Goldstein et al., 2005; Raskin et al., 2005), using the BPI average 
pain score. This enabled an estimate of five subjects necessary for 80% power, to 
demonstrate at the 5% level of significance, pre and post treatment effects of 
duloxetine in relieving pain. From this information it was considered prudent to enrol 
thirty subjects onto each arm of the study. Due to ongoing recruitment problems, the 
decision was made to finish the study with eighty-three patients randomised onto the 
trial.
All statistical analysis was performed using the SAS® statistical analysis package 
Version 9.1.3, or later (SAS Institute, Cary, North Carolina, USA). A significance 
level of at least p <0.05 was used to state whether a result was significant or not.
Primary variables and secondary variables were analysed using a repeated measures 
general linear mixed model. This model was selected as it was deemed to be the most 
appropriate method of analysing the variables, being able to take into account the
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complex covariation of the repeated measurements, at the three periods, within each 
subject. The analysis looked at change from visit 1 (baseline placebo) to visit 2 (low 
dose) within each treatment, change from visit 1 to visit 3 (high dose) within each 
treatment. Change from visit 1 to visit 2 between treatments was analysed, along with 
change from visit 1 to visit 3, and from visit 1 to the combination of visit 2 and 3 
between treatments. The analysis also looked at changes over all hours for visit 1 to 
Visit 2, and from visit 1 to visit 3.
9.1. Further exploratory analysis
Further exploratory analysis was conducted using SAS. Regression analysis was 
performed on the majority of the baseline measurements (where appropriate) to 
explore possible associations between the variables at baseline.
To further explore BPI and Quality of Life, the worst pain score was taken as a 
reference point, and all patients with a baseline worst pain score of 0-3 were labelled 
as having mild pain, all patients with a baseline worst pain score of 4-6 labelled as 
having moderate pain, and all patients with a baseline worst pain score of 7-10 were 
labelled as having severe pain. Pearson correlations were then used to look at 
associations between all of the BPI pain scores in relation to the SF-36 scores, within 
each pain group.
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Chapter 3: Baseline results
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10. Baseline Results
10.1. Baseline characteristics
10.1.1. Demographics
Of the 90 patients planned to participate, a total of 83 patients were randomised to 
take part in this study, 65 patients completed all visits of the study (see Figure 8). The 
mean age for the patients was 65.1 years (age range 38 to 82). Of the 83 patients, 57 
were male, and the mean BMl was 32.1kg/m2 (SD 5.2). A report by WHO classifies a 
BMl of 30 -  34.99 as Obese Class 1 and with a moderate risk of co-morbidities (WHO 
2000). Table 3 displays the demographics of these patients and how they were 
distributed amongst the treatment arms.
Pregabalin
N = 2 1
Duloxetine 
A  = 28
Amitriptyline 
A  = 2 8
Total 
A  = 83
Sex Male 1 9(704% 0 19(67.9% ) !9(6% 9% 0 57(68 .7% )
Female 8 ( 2 9 jA 0 9(32T % 0 9(32T % 0 2 6 (3 L 3 % )
Age (years) Mean (SD) 66.3 (7.5) 65.0 (9.6) 64.2 (9.6) 65.1(8.9)
Min 5 5 2 39 2 3%9 3T9
Max 81.6 80.4 7 9 2 8L6
BMl (kg/m2) Mean (SD) 32.1(5.2) 3 Z 0 (5 2 ) 31.9 (5.6) 32.0 (5.4)
Min 182 2 3 2 202 182
Max 40.0 39 2 41.9 41.9
Table 3. A table displaying the demographic characteristics of patients randomised onto this 
study, including the distribution of demographics between treatment groups
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10.1.2. Subjective pain
Subjective pain was measured using the brief pain inventory (BPI) and a visual 
analogue scale (VAS), which was taken from the Short Form McGill Pain 
Questionnaire (Melzack 1987)
A total of 73 subjects had complete BPI data at baseline (more data was available at 
baseline than end of study due to patient discontinuation during the study). Table 4 
displays the baseline scores for the BPI severity measure and associated questions, 
total mean scores are displayed as well as how the scores were distributed between the 
treatment groups. The mean baseline BPI severity score was 3.3 with a range from 0 
(no pain) -  10 (worst pain). The BPI severity score is comprised of four individual 
pain scores, baseline worst pain (mean score = 4.6), least pain (mean score = 2.4), 
average pain (mean score = 3.6), and current pain (mean score = 2.7).
Baseline (placebo) Baseline (placebo) Baseline (placebo) Total Baseline
scores for the Pregabalin scores for the scores for the (placebo scores
group Duloxetine group Amitriptyline group for all patients
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
BPI
Severity
25 3.1(2.10) 23 3.4 (2.26) 25 3.5 (2.04) 73 3/3(2.11)
BPI Worst 
Pain
25 23 4.7 (2.93) 25 4.6 (2.74) 73 4X5(2.68)
BPI Least 
Pain
25 2/2(2.31) 23 2.6 (2.25) 25 2.4 (1.93) 73 2.4(2.14)
BPI
Average
Pain
25 1 3 ( 2 1 4 ) 23 3.7 (2.29) 25 3.8 (2.09) 73 3.6(2.15)
BPI
Current
Pain
25 2.2 (2.27) 23 2.8(2.21) 25 3.1 (2.39) 73 2.7 (2.30)
Table 4. A table displaying the baseline scores for the BPI severity measure and associated 
questions. A total of 73 patients had complete baseline data for the BPI, the mean scores for all 73 
patients are displayed along with how this was distributed within the treatment groups. The BPI 
severity score is comprised of four pain scores, worst pain, least pain, average pain, and current 
pain.
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Baseline scores for the BPI interference are displayed in Table 5. The collective 
patient group had a mean baseline pain interference score of 2.6 with a range of 0 -  8. 
The BPI interference score was comprised of scores from seven questions which 
measure the interference of pain on general activity (mean score = 2.8), mood 
(mean score = 1.8), walking ability (mean score = 3.3), normal work 
(mean score = 2.5), relations with other people (mean score = 1.5), sleep 
(mean score = 3.6), and enjoyment of life (mean score = 2.6).
These baseline scores indicated that the aspects of life most affected by pain in this 
sample were sleep and walking ability, as measured by the BPI.
Pain was also measured using a 100mm (0 = no pain and 100 = worst possible pain) 
visual analogue scale. The mean VAS score at baseline was 23.3 see Table 5
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Baseline (placebo) Baseline (placebo) Baseline (placebo) Total Baseline
scores for the scores for the scores for the (placebo) scores
Pregabalin group Duloxetine group Amitriptyline for all patients
group
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
BPI Interference 25 2.4(2.13) 22 2.9 (2.29) 26 2.4 (2.24) 73 2.6 (2.20)
BPI General 
Activity
25 2.6 (2.55) 22 3.2 (2.87) 26 2.7 (2.46) 73 2.8 (2.60)
BPI Mood 25 1.5(1.83) 22 2.0(1.94) 26 1.8(2.25) 73 1.8(2.00)
BPI Walking 
Ability
25 3.5(3.15) 22 3.8(3.19) 26 2.7 (2.53) 73 3.3 (2.95)
BPI Normal 
Work
25 2.5(2.31) 22 2.9 (2.67) 26 2.3 (2.63) 73 2.5 (2.52)
BPI Relations 
with Other
25 1.1 (1.59) 22 2.0 (2.09) 26 1.5 (2.34) 73 1.5(2.04)
People
BPI Sleep 25 3.1 (2.50) 22 3.9(3.07) 26 3.8(2.78) 73 3.6 (2.76)
BPI Enjoyment 
o f Life
25 2.8 (2.93) 22 2.7 (2.27) 26 2.2(3.01) 73 2.6 (2.75)
Visual Analogue 
Scale
25 16.8(19.57) 23 23.3 (24.28) 26 29.6(22.91) 74 23.3 (22.84)
Table 5. A table displaying the baseline scores for the BPI interference measure and associated 
questions, the BPI interference score is comprised of scores for how pain interferes on general 
activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of 
life. Total baseline scores are displayed (N=73) as well as how they were distributed amongst the 
treatment groups. Baseline visual analogue scale data is also displayed.
10.1.3. Baseline Quality of life
Quality of life (QoL) was measured at medieal screening using the SF-36 version 2. 
Scores for the SF-36 range from 0 to 100, with higher scores indicating a better health 
state. The SF-36 was again completed on the last day of the study. Day 36. Table 6 
displays the QoL scores as collected at screening, they have been divided into the 
treatment groups to show how the scores were distributed between the groups at the 
screening phase. Total screening scores are also displayed.
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Screening scores Screening scores for Screening scores Total screening
for the Pregabalin the Duloxetine for the scores for all
group group Amitriptyline patients
_________________________________________ group
N Mean (SD) N Mean (SD) N Mean
(SD)
N Mean
(SD)
SF36
Physical
Functioning
Score
2^ 36.9(8.21) 23 37.8(11.62) 23 40.8 (10.26) 70 38.5(10.10
SF36 Role
Physical
Score
24 39.5 (12.46) 23 41.5(11.10) 23 44.8(11.05) 70 41.9(11.62)
SF36 Bodily 
Pain Score
24 39.9 (6.77) 23 37.7 (9.33) 23 40.1 (8.09) 70 39.2 (8.06)
SF36 General 
Health Score
24 37.5 (8.63) 23 44.6(9.21) 23 418(9 37) 70 41.6 (9.45)
SF36 Vitality 
Score
2^ 42.7 (8.73) 23 46.1 (9.17) 23 45.2 (7.64) 70 44.6 (8.54)
SF36 Social 
Functioning 
Score
2^ 46.2(10.11) 23 45.7(12.25) 23 46.4(10.52) 70 46.1 (10.83)
SF36 Role 
Emotional 
Score
24 47.8 (12.34) 23 45.4(11.33) 23 48.3(11.92) 70 47.2(11.77)
SF36 Mental 
Health Score
24 52.0 (8.24) 23 48.3(7.91) 23 50.3 (7.10) 70 50.2(7.81)
SF36 Mental
Component
Summary
24 52.8(9.31) 23 50.2 (8.98) 23 51.1(7.26) 70 51.4(8.52)
SF36 Physical
Component
Summary
24 34.2 (8.22) 23 37.8 (10.00) 23 39j(9J3) 70 37.1 (9.34)
Table 6 Screening (baseline) scores for the SF-36, and how these scores were distributed between 
the treatment groups, as well as total scores
10.1.4. Baseline cognitive function
Cognitive testing was conducted four times on Day 8 (after thorough training the 
previous day). This Day 8 data represents the baseline scores as patients had been on 
placebo since Day 1. Mean baseline scores are reported in Table 7, total scores are 
displayed as well as scores by treatment group, to demonstrate the baseline score of 
each treatment group before they moved on to the treatment phase. For the Stroop task 
there were fewer data, as some patients (11) were colour-blind and therefore their data 
were not included in analysis.
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Baseline 
(placebo) 
scores for the 
Pregabalin 
group
Baseline 
(placebo) 
scores for the 
Duloxetine 
group_______
Baseline 
(placebo) 
scores for the 
Amitriptyline 
group_______
Total 
Baseline 
(placebo) 
scores for all 
patients
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
Stroop Valid 20 778.7 21 794.8 25 782.4 66 78^2
Responses Reaction (113.00) (118.00) (81.11) (123.72)
Time (ms)
CTT Mean Deviation 25 14.0 23 17.0 26 16.6 74 15.9
(pixels) (13.35) (10.20) (10.19)
Sternberg Memory 25 83&6 23 911.6 26 845.2 74 8626
Reaction Time (139.00) (136.09) (175.57) (154.94)
Overall (ms)
OFF Mean Threshold 25 27.1 23 28.0 25 2 2 2 73 2 2 4
Frequency (Hz) (3.11) (2.74) (2.05)
CRT Recognition 25 5420 23 47&8 26 4854 74 5023
Reaction Time (ms) (269.36) (114.81) (111.11) (183.13)
CRT Motor Reaction 25 329^ 23 33T8 26 323d 74 328T
Time (ms) (72.91) (78.54) (70.90) (73.90)
CRT Total Reaction 25 871.7 23 812.6 26 808.1 74 831.0
Time (ms)
(303.50) (151.39) (155.08)
217.33
DSST Total Number 25 2 9 J 23 30.1 26 28T 74 2 2 4
of Responses (7.77) (&41) (8.48)
DSST Number of 25 2&6 23 29H 26 2 2 7 74 225
Correct Responses (8.03) (8.70) (9.35) (8.71)
Immediate Word 25 7.0 23 7.5 26 6.3 74 6.9
Recall (number
correct)
Delayed Word Recall 25 2.7 23 4.1 26 3.0 74 3.2
(number correct) ^ 3 % (3.16) (2.85) ^ 8 ^
Table 7. Mean baseline scores for the cognitive tests, total scores displayed as well as scores for 
each treatment group.
10.2. Baseline analysis
Exploratory regression analysis was performed on all variables to investigate possible 
associations between variables.
10.2.1. Pain and Quality of life
Baseline BPI severity scores were negatively associated with the majority of the 
screening SF-36 scores, including the physical component summary and the mental 
component summary, suggesting as pain increases QoL decreases, see Table 8.
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When comparing mean baseline BPI interference scores with the screening SF-36 
scores, there was also a negative correlation between the BPI interference score and 
all SF-36 scores including the two component summaries (p <0.05). This indicated 
that as pain interference increased, the QoL scores decreased suggesting a negative 
impact by pain interference on all aspects of quality of life.
The baseline visual analogue scale also negatively correlated with some of the 
screening SF-36 scores, with an increase in pain associated with a lower QoL, see 
Table 9.
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10.2.2. Subjective pain and sleep
Baseline pain scores and baseline subjective measures of sleep were included in the 
regression analysis. Subjective night-time sleep quality was measured in the patient 
diary using a rating scale from 1 - 9 ,  with 1 representing the best sleep, and 9 the 
worst. Daytime sleepiness was measured using the KSS, where 1 = very alert,
3 = alert, 5 = neither alert nor sleepy, 7 = sleepy, 9 = very sleepy. Individuals could 
also select the numbers in-between these rating points.
All correlations between the BPI and quality of sleep/daytime sleepiness scores were 
positive, indicating that with increased pain, quality of sleep is poorer and daytime 
sleepiness levels are increased.
The baseline VAS score also negatively correlated with quality of sleep/daytime 
sleepiness scores, see Table 10.
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Subjective KSS
quality o f (daytime
sleep sleepiness)
BPI Severity 0.58323 0.33446
<.0001 0.0951
V - 6 P # = 7 4
BPI Worst Pain 0.58192 0.51114
0.0021 0.0319
V = 6P # = 7 4
BPI Least Pain 0.54563 0.16332
0.0003 0.4250
V - 6 P # = 7 4
BPI Average Pain 0.62800 0.32008
<.0001 0.II83
# = 7 4
BPI Current Pain 0.57736 0.30882
0.0004 0.1573
V = 69 # = 7 4
BPI Interference 0.57671 0.44819
0.0001 0.0118
V  = 6P # = 7 4
BPI General 0.50815 0.45145
Activity 0.0064 0.0434
A  = 69 # = 7 4
BPI Mood 0.36934 0.34728
0.0050 0.0279
V = 69 # = 7 4
BPI Walking 0.64402 0.62145
Ability 0.0013 0.0095
A^  = 69 # = 7 4
BPI Normal Work 0.68623 0.47469
<.0001 0.0230
#  = 69 # = 7 4
BPI Relations 0.38900 0.23332
with Other People 0.0048 0.1756
#  =  69 # =  74
BPI Sleep 0.67519 0.55539
0.0002 0.0147
# = 6 9 # = 7 4
BPI Enjoyment o f 0.54725 0.46327
Life 0.0025 0.0408
#  = 69 # = 7 4
Visual Analogue 4.55448 3.28746
Scale 0.0017 0.0851
#  = 69 # = 7 4
Table 10. Baseline correlations between all of the BPI scores and  subjective quality of sleep, and 
KSS scores. V isual analogue scale scores also correlated. Significant correlations a re  em boldened. 
All correlations between the BP W A S  and the sleep ratings were of positive direction indicating 
th a t as pain increases quality of sleep decreases and daytim e sleepiness levels increase. The 
num ber of participan ts is different due to the am ount of data available.
81
10.3. Further exploration o f pain and Q uality o f life
Previous work in pain research has categorised patients into groups representing pain 
intensity using the BPI (Serlin et ah, 1995). Typically this has been based on the 
‘worst pain’ score with patients being divided into either mild 0-3, moderate 4-6, or 
severe 7-10. Based on these cut-off points there were 23 patients identified as having 
mild pain, 30 with moderate pain, and 16 with severe pain at baseline.
Further analysis was performed on these subgroups to more fully explore the 
associations between pain and QoL.
10.3.1. Mild pain and quality of life
All associations between the BPI scores and SF-36 scores were negative, indicating 
that with increased pain, QoL was lowered.
In the group categorised as having mild pain, the BPI severity score correlated with 
the physical function score of the SF-36 (p <0.05) but not with any of the other 
questions or either of the summary scores, see Table 11.
In contrast the BPI interference score correlated with all of the SF-36 component 
scores apart from the general health and the role physical component. Both of the 
SF-36 summary scores correlated with BPI interference (p <0.05), see Table 12.
Overall, at baseline, the patients in the mild group had significant associations 
between pain that was rated as interfering with daily activities, and quality of life.
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10.3.2. Moderate pain and quality of life
In the moderate group, the BPI severity only correlated with the mental health 
component score of the SF-36 (p <0.05). This remained the case for two of the four 
individual questions that produce the BPI severity score, average and current pain. 
There was also a correlation between the worst pain question and the vitality 
component score of the SF-36 (p <0.05), see Table 13.
In the moderate pain group, the BPI interference score correlated with the following 
individual QoL component scores: bodily pain, general health, physical functioning, 
role physical, and vitality (p <0.05). Only the physical component summary correlated 
with BPI interference (p <0.05) see Table 14.
When looking further at the individual questions that comprise the BPI interference 
score, most of them correlated with the SF-36 component scores in the same way that 
the overall interference score correlated with the SF-36, so as pain increased QoL 
decreased.
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10.3.3. Severe pain and quality of life
In the severe group there were no correlations between the BPI severity score and the 
individual SF-36 component scores, see Table 15.
There were however correlations between the BPI severity and both of the SF-36 
component summary scores (p <0.05).
In the severe pain group, the BPI interference score correlated with the following 
SF-36 individual component scores: bodily pain, general health, mental health, 
physical functioning, and role physical (p <0.05). BPI interference also correlated 
with both the physical component summary and mental component summary (p <0.05) 
see Table 16.
When looking further at the individual questions that comprise the BPI interference 
score, most of them correlated with the individual SF-36 component scores in the 
same way that the overall interference score correlated with the SF-36; so as pain 
severity increased, QoL decreased.
10.4. Pain and cognition
Baseline pain scores were analysed in comparison to the baseline cognitive test scores 
(as measured on Day 8, placebo baseline). There were no consistent associations 
between any of the pain scores and any of the cognitive measures, suggesting no 
measurable impact on baseline cognitive function by pain.
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11. Summary and discussion of baseline characteristics
The baseline charaeteristies provide information on the patient group enrolled onto 
this thesis study. Eighty three patients were randomised with a mean age of 65.1 years 
and a mean BMI of 32.1 (class 1 obese as classified by WHO guidelines from 2000).
Demographic characteristics were comparable across the three groups of subjects 
compared. Baseline symptom scores and QoL measures were also comparable across 
the three groups. With regards to subjective pain scores, baseline data was available 
for 73 patients. The mean BPI severity score was 3.3 and the mean BPI interference 
score was 2.6, with a mean VAS score of 23.3. These pain scores are low as compared 
to other studies investigating pain in this patient group. In a study by York and 
Gordon (2009) the BPI severity score was 4.9 for their treatment group and 5.1 for 
their control group. The BPI interference score was 4.7 for their treatment group at 
baseline, and 5.5 for the control group. Hoffman et al., (2009) used a modified version 
of the BPI and the baseline BPI severity score was 6.6 and the BPI interference score 
was 5.2 (see Table 21).
Baseline QoL was also recorded (N= 70) using the SF-36. For the mental component 
summary there was a mean score of 51.4, and for the physical component summary a 
mean score of 37.1. Compared to other studies investigating quality of life in this 
patient group, the scores for the physical component summary and the mental 
component summary are higher in this thesis study, suggesting a higher quality of life. 
In a study by Swisloeki et al., (2009) there were two groups; for the placebo group at 
baseline the physical component summary score was 31.4 and the mental component 
summary score was 43.8. For the treatment group at baseline the physical component 
summary score was 34.9 and the mental component score was 43.7. Conversely
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compared to a study by Armstrong et al., (2007), the patients in this thesis study have 
a poorer quality of life. The Armstrong study didn’t report the scores for the physical 
or mental component summaries but for seven out of the eight scores which comprise 
the summary scores, the scores are higher in the Armstrong study suggesting 
improved quality of life.
Cognitive function was also assessed at baseline, although some of the stroop data 
were not included as the patients were colour-blind.
Baseline measures were explored through regression analysis and the BPI severity 
score was negatively associated with quality of life scores, in particular the physical 
component summary and the mental component summary. The BPI interference score 
was also found to negatively correlate with the two summary component scores. This 
data supports previous findings that the pain experienced by these patients has a 
negative impact on QoL. Therefore as pain increases quality of life decreases and this 
is reflected in both of the summary scores (Galer et al., 2000; Smith and Nicholson, 
2007; Turk and Melzack, 2001).
The subjective pain ratings also correlated with subjective sleep ratings indicating that 
with increased pain, daytime sleepiness is increased and overall sleep quality 
decreases. This data supports previous research that pain has a detrimental effect on 
sleep (Gore et al., 2005; Menefee et al., 2000; Morin et al., 1998). This impact by pain 
on sleep is of interest as it is plausible that decreased sleep quality will have a 
detrimental effect on other aspects of daily life such as poorer daytime performance 
and reduced quality of life. With the suggestion that poor sleep also lowers the pain 
threshold (Chiu et al., 2005) this indicates a vicious circle of pain and sleep. This
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thesis data is evidence that pain disrupts sleep which can further confound patient 
outcomes in a painful condition that is already difficult to manage and treat effectively.
When looking at baseline cognitive function scores in comparison to baseline pain 
scores there were no consistent associations. Previous research in patients with non- 
malignant pain and cognitive function (Sjogren et al., 2005) included a control group 
and reported that individuals with a painful condition have poorer cognitive 
performance as compared to healthy individuals. Future research in this area would 
benefit from an age-matched healthy control group and/or a control group with just 
diabetes and not painful DPN.
This study had no control group and the data show no measurable impact on cognitive 
function by pain. One hypothesis for this lack of effect is that the patients are able to 
cope with their pain with regards to cognitive processing and the pain is not 
distracting them. From this point of view this data does not support the research by 
Eeeleston et al. (1999) that pain demands attention. It may also be possible that the 
pain experienced by the patients in this thesis study was not severe enough to 
‘demand attention’, especially as the pain scores were relatively low in comparison to 
other studies investigating painful DPN.
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Chapter 4: Pharmacodynamic results
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12. Pharmacodynamie results
12.1. Treatment effect on Subjective Pain
Subjective pain was measured using the BPI and a visual analogue scale.
Measurements were taken on a daily basis, during the seven day placebo run-in and 
throughout the twenty-eight day active treatment period.
For all BPI scores a reduction in the score is positive as it represents less pain. When 
answering the BPI questions, the individuals rated from 0 - 1 0  with 0 being the 
positive end of the scale and 10 being the negative end.
12.1.1. BPI pain severity
The BPI severity score stands alone as a measurement of pain; it is the average score 
for worst pain, least pain, average pain, and current pain. The data for changes in BPI 
pain severity with treatment is reported in the following sections, see Table 17 for 
mean BPI severity scores.
Placebo Pregabalin_________________Duloxetine_________________ Amitriptyline
Low dose High dose Low dose High dose Low dose High dose
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
A Mean
(SD)
BPI Severity 73 3.3 20 2.3 19 2.4 23 2.5 23 2.2 23 2.7 23 2.6
(2.11) (2.08) (1.90) (2.12)
(1.65) (1.57)
BPI Worst 73 4.6 20 3.8 19 3.9 23 3.4 23 3.3 23 3.8 23 3.7
Pain (2.68) (2.31) (2.64) (2.74) (2.75) (2.85)
BPI Least 73 2.4 20 1.5 19 1.6 23 1.8 23 1.4 23 1.8 23 1.7
Pain (2.14) (1.64) (1.30) (1.97) (1.83) (1.47) (1.84)
BPI 73 3.6 20 2.4 19 2.4 23 2.7 23 2.3 23 2.9 23 2.7
Average
Pain
(2.15) (1.53) (1.64) (2.32) (2.21) (1.96) (2.14)
BPI Current 73 2.7 20 1.8 19 1.7 23 2.0 23 1.9 23 2.2 23 2.2
Pain (1.77) (1.20) (1.81) (2.02) (2.11) (2.29)
G 3 0 )
Table 17. Mean pain severity scores and mean scores for each of the questions that produce the 
pain severity score. Scores displayed for all treatment periods by treatment group.
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For BPI severity there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,65.56) = 8.57, P < 0.001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a reduced BPI severity score 
(indicating less pain) (Cohen’s d 0.49, P < 0.05, Cohen’s d 0.68, P < 0.01, and 
Cohen’s d 0.56, P < 0.05 respectively). From visit 1 to visit 3 (high dose) patients in 
the duloxetine group had a reduced BPI severity score (Cohen’s d 0.62, P < 0.05). See 
Figure 9
4.5
3.5
Q.
2.5
1.5
low-dose (Day 22)Placebo (Day 8) high-dose (Day 36)
Figure 9 Figure to show trea tm en t effect on pain severity a t each visit of the study.
Pain severity scores for pregabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), at Day 8, Day 22, and 
Day 36, data  points represen t mean pain severity, whilst the e rro r  bars display the SE.
12.1.1.1. BPI worst pain
For BPI worst pain there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63.67) = 5.90, P < 0.01).
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From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group, 
had a reduced BPI worst pain score (indicating less pain) (Cohen’s d 0.67, P < 0.01). 
See Figure 10. Table 17 displays the mean scores for each visit.
low-dose (Day 22) high-dose (Day 36)placebo (Day 8)
Figure 10 A figure displaying the worst pain scores throughout the study.
Worst pain scores for pregabalin (♦), duloxetine (■), amitriptyline (A), at Day 8, Day 22, and 
Day 36, data points represent mean worst pain, whilst the error bars display the SE.
12.1.1.2. BPI least pain
For BPI least pain there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63.94) = 7.67, P < 0.001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group 
and duloxetine group, had a reduced BPI least pain score (indicating less pain) 
(Cohen’s d 0.54, P < 0.05 and Cohen’s d 0.67, P < 0.01 respectively). From visit 1 to 
visit 3 (high dose) patients in the duloxetine group, had a reduced BPI least pain score 
(Cohen’s d 0.78, P < 0.01 ), see Figure 11.
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2.5
CL
0.5
placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
Figure 11 A figure displaying the changes in least pain scores recorded a t baseline, low-dose, and 
high-dose.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t m ean least pain, whilst 
the e rro r  bars display the SE.
12.1.1.3. BPI average pain
For BPI average pain there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63 49) = 10.59, P < 0.0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a reduced BPI average pain score 
(indicating less pain) (Cohen’s d 0.54, P < 0.05, Cohen’s d 0.75, P < 0.01, and 
Cohen’s d 0.58, P < 0.05 respectively). From visit I to visit 3 (high dose) patients in 
the duloxetine group and amitriptyline group, had a reduced BPI average pain score 
(Cohen’s d 0.61, P < 0.05 and Cohen’s d 0.59, P < 0.05 respectively). See Figure 12.
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placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
Figure 12 A figure displaying the average pain scores for each trea tm en t group a t baseline, low- 
dose, and high-dose.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A) ,  data points represen t mean average pain, 
whilst the e rro r  bars display the SE.
12.1.1.4. BPI current pain
For BPI current pain there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,64,39) = 5.08, P < 0.01).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
and amitriptyline group had a reduced BPI current pain score (indicating less pain) 
(Cohen’s d 0.64, P < 0.05 and Cohen’s d 0.63, P < 0.05 respectively). From visit 1 to 
visit 3 (high dose) patients in the amitriptyline group, had a reduced BPI current pain 
score (Cohen’s d 0.50, P < 0.05). See Figure 13.
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high-dose (Day 36)placebo (Day 8) low-dose (Day 22)
Figure 13 A figure displaying the cu rren t pain scores for the th ree trea tm en t groups a t baseline, 
low-dose, and high-dose.
Pregabalin (♦ ) ,  duloxetine (H ), am itrip ty line (A) ,  data points represen t m ean cu rren t pain, 
whilst the e rro r  bars display the SE.
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12.1.2. BPI interference
The BPI interference score is comprised of seven components, interference on; 
general activity, mood, walking ability, normal work, relations with other people, 
sleep, and enjoyment of life. These components are described in more detail in the 
following sections. The BPI interference score also stands alone as a measurement of 
the level of interference by pain on the everyday activities of an individual. See Table 
18 for mean data scores.
Placebo Pregabalin Duloxetine Amitriptyline
Low dose High dose
N Mean
(SD)
N  Mean 
(SD)
N  Mean 
(SD)
Low dose 
N  Mean 
(SD)
High dose Low dose High dose
N  Mean 
(SD)
N  Mean 
(SD)
N  Mean 
(SD)
BPI 73 2.6 21 2.3 18 2.6 23 2.3 23 1.9 24 1.9 23 1.6
Interference (2.23) (2.25) (2.14) (2.26) (1.98) (1.69)
BPI General 73 2.8 21 2.8 18 3.3 23 2.7 23 2.2 24 2.0 23 1.6
Activity (2.91) (2.82) (2.86) (L9%
BPI Mood 73 1.8 21 1.4
(l.% 0
18 1.3
(1.57)
23 1.4
(1.56)
23 L I
(1.73)
24 1.6
(2.02)
23 1.1
(1.59)
BPI 73 3.3 21 3.1 18 3.6 23 3.0 23 2.5 24 2.5 23 2.5
Walking 
Ability 
BPI Normal
(2.95) (2.81) ^ 2 % (2.33)
73 2.5 21 2.4 18 2.8 23 2.2 23 1.9 24 1.9 23 1.6
Work (2.40) (2.51) (2.28)
BPI 73 1.5 21 1.3 18 1.3 23 1.3 23 1.0 24 1.3 23 1.0
Relations (1.6% (1.53) (1.74) (1.72) (1.80) (1.36)
with Other
People
BPI Sleep 73 3.6 21 2.7 18 2.9
(2.82)
23 3.3
(3.35)
23 2.5
(2.95)
24 2.7
(2.84)
23 2.0
(2.60)
BPI 73 2.6 21 2.5 18 2.8 23 2.2 23 1.9 24 1.7 23 1.6
Enjoyment 
o f Life
(2.75) (2.98) (3.04) (2.43) (2.23) (2.35) (1.83)
Visual 74 2T3 20 LL5 19 13.2 23 16.3 23 13.2 24 22 3 23 2T6
Analogue (22.84) (19.10) (14.85) (21.58) (20.92) (20.88) (23.12)
Scale
Table 18. M ean pain interference scores and mean scores for each of the questions th a t produce 
the pain interference score. Scores displayed for all trea tm en t periods by trea tm en t group.
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For BPI interference there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,62.82) = 8.06, P < 0.001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
had a reduced BPI interference score (indicating less interference by pain)
(Cohen’s d 0.66, P < 0.01). From visit 1 to visit 3 (high dose) patients in the 
duloxetine group, had a reduced BPI interference score (Cohen’s d 0.91, P < 0.001). 
See Figure 14.
3.5
1.5
placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
Figure 14 A figure displaying BPI interference scores for each trea tm en t group a t baseline, low- 
dose, and high-dose.
Pregabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A) ,  data points represen t mean pain in terference, 
whilst the e rro r  bars display the SE.
12.1.2.1. BPI general activity
For BPI general activity there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63.39) -  3.97, P < 0.05).
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From visit 1 (placebo baseline) to visit 2 (low dose), patients in the amitriptyline 
group had a reduced BPI general activity score (indicating less interference by pain on 
general activity) (Cohen’s d 0.59, P < 0.05). From visit 1 to visit 3 (high dose) 
patients in the duloxetine group, had a reduced BPI general activity score 
(Cohen’s d 0.70, P < O.OI). See Figure 15.
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placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
F igure 15 A figure displaying the scores for in terference by pain on general activity at each visit 
of the study.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t m ean in terference w ith 
general activity, whilst the e rro r  bars display the SE.
12.1.2.2. BPI mood
For BPI mood there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63.69) = 4.09, P < 0.05).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
had a redueed BPI mood score (indicating less interference by pain on mood) 
(Cohen’s d 0.50, P < 0.05). From visit 1 to visit 3 (high dose) patients in the
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duloxetine group, had a reduced BPI mood score (Cohen’s d 0.82, P < 0.01). See 
Figure 16.
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placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
Figure 16 A figure displaying the scores for interference by pain on mood.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean interference on 
mood, whilst the error bars display the SE.
12.1.2.3. BPI walking ability
For BPI walking ability there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,62.00) = 3.19, P < 0.05).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
had a reduced BPI walking ability score (indicating less interference by pain on 
walking ability) (Cohen’s d 0.55, P < 0.05). From visit 1 to visit 3 (high dose) patients 
in the duloxetine group, had a reduced BPI walking ability score (Cohen’s d 0.75, P < 
0.01). See Figure 17.
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1.5
placebo (Day 8) low-dose (Day 22) high-dose (Day 36)
Figure 17 A figure displaying the interference by pain on walking ability.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean interference on 
walking ability, whilst the error bars display the SE.
12.1.2.4. BPI normal work
For BPI normal work there was no significant treatment or treatment by time effect. 
There was a significant visit effect (F (2,61.75) = 5.20, P < 0.01).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
had a reduced BPI normal work score (indicating less interference by pain on normal 
work) (Cohen’s d 0.71, P < 0.01). From visit 1 to visit 3 (high dose) patients in the 
duloxetine group, had a reduced BPI normal work score (Cohen’s d 0.99, P < 0.001). 
See Figure 18.
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3.5
1.5
low-dose (Day 22) high-dose (Day 36)placebo (Day 8 )
Figure 18 A figure displaying the interference by pain on normal work scores.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean interference on 
normal work, whilst the error bars display the SE.
12.1.2.5. BPI relations with other people
For BPI relations with other people there was no significant treatment, or treatment by 
time effect, or significant visit effect. See Figure 19.
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placebo (Day 8 ) low-dose (Day 22) high-dose (Day 36)
Figure 19 A figure displaying the interference by pain on relations with other people. 
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean interference on 
relations with other people, whilst the error bars display the SD.
12.1.2.6. BPI sleep
For BPI sleep there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,63.35) = 12.98, P <.0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a reduced BPI sleep score (indicating 
less interference by pain on sleep) (Cohen’s d 0.67, P < 0.01, Cohen’s d 0.52, P < 0.05, 
and Cohen’s d 0.83, P < 0.01 respectively). From visit 1 to visit 3 (high dose), patients 
in the duloxetine group, and amitriptyline group had a reduced BPI sleep score
(Cohen’s d 0.51, P < 0.05, Cohen’s d 0.76, P < 0.01, and Cohen’s d 0.75, P < 0.01 
respectively). See Figure 20.
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Figure 20 A figure displaying the interference by pain on sleep.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean interference on 
sleep, whilst the error bars display the SE.
12.1.2.7. BPI enjoyment of life
For BPI enjoyment of life there was no significant treatment or treatment by time 
effect.
There was a significant visit effect (F (2,62.23) = 4.07, P < 0.05).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
had a redueed BPI enjoyment of life score (indicating less interference by pain on 
enjoyment of life) (Cohen’s d 0.65, P < 0.05). From visit 1 to visit 3 (high dose), 
patients in the duloxetine group had a reduced BPI enjoyment of life score (Cohen’s d 
0.72, P < 0.01). See Figure 21.
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placebo (Day 8 ) low-dose (Day 22) high-dose (Day 36)
Figure 21 A figure displaying the interference of pain on enjoyment of life.
Pregabalin (♦), duloxetine (■), amitriptyline (A) ,  data points represent mean interference on 
enjoyment of life, whilst the error bars display the SE.
12.1.3. Visual Analogue Scale
The VAS used was taken from the Short Form McGill Pain Questionnaire (Melzack 
1987). Patients were asked to rate their pain on a 100mm line scale, with the left end 
equalling no pain, and the right end worst possible pain.
For the VAS there was no significant treatment or treatment by time effect.
There was a significant visit effect (F (2,65.06) = 12.43, P <.0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a redueed VAS score (indicating less 
pain) (Cohen’s d 0.60, P < 0.05, Cohen’s d 0.76, P < 0.01, and 
Cohen’s d 0.68, P < 0.01 respectively). From visit 1 to visit 3 (high dose), patients in
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the duloxetine group had a reduced VAS score (Cohen’s d 0.88, P < 0.001). See 
Figure 22.
GO
low-dose (Day 22)placebo (Day 8 ) high-dose (Day 36)
Figure 22 A figure displaying the VAS scores for each treatment group at baseline, low-dose, and 
high-dose.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean VAS scores, whilst 
the error bars display the SE.
12.2. Quality of life
For Quality of life there was no significant treatment or treatment by time effect.
There was a significant visit effect for the role physical component score 
(F ( 1, 63.52) ^ 8.05, P < 0.01).
From medical screening (placebo baseline) to last study day (high dose), patients in 
the pregabalin group had a reduced role physical component score (Cohen’s d 0.50, P 
< 0.05). A higher score indicates a higher quality of life so this score reduction 
indicates a decrease in quality of life for this SF-36 variable.
See Table 19 for a tabulation of the SF-36 scores at screening and at Day 36 (high 
dose).
10
See Figure 23 for a graphical presentation of change from baseline for each treatment 
group.
(10.75) (11.09) (8.16)
Pregabalin Pregabalin Duloxetine Duloxetine Amitriptyline Amitriptyline
(screening) (high dose) (screening) (high dose) (screening) (high dose)
N  Mean N  Mean N  Mean N  Mean N  Mean N  Mean
(SD) (SD) (SD) (SD)
____________________________________________________________ (SD)__________ (SD)
SF 36 2^  36.9 35.0 23 37.8 23 37.2 23 40.8 2/ 38.9
Physical (10.13) (11.62) (11.80) (10.26)
Score'’"’"® («21) (7.39)
SF36 Role 24 39.5 19 33.9 ^3 41.5 23 3 3  4  23 44.8 21 4 pg
Physical (11.10) (11.05)
(12.46) (10.14) (10.52) (10.02)
SF36 24 39.9 79 ggg 23 37.7 23 4 2 2  23 40.1 27 4 2 4
Bodily Pain (6.77) ' (9.33) ' (8.09)
(8.65) (7.99) (7.79)
SF36 24 37.5 79 3 7 0  23 44.6 23 4 0  ^ 23 42.8 27 4 2 5
General (8.63) ' (9.21) ' (9.37)
Health 
Score
SF36 24 42.7 79 4 0  g 23 46.1 23 4 5 0  23 45.2 27 4 ^ 1
Vitality (8.73) ' (9.17) ' (7.64)
(11.74) (9.52) (7.11)
SF36 Social 24 46.2 79 4 4  g 23 45.7 23 4 7  1 23 46.4 27 4 7  q
Functioning (10.11) ' (12.25) ' (10.52)
(11.15) (11.03) (8.90)
SF36Role 24 47.8 79 4 5 7  23 45.4 23 4 ^ 9  23 48.3 27 4 ^ 4
Emotional (12.34) ' (11.33) ' (11.92)
(11.75) (12.33) (9.95)
SF36 24 52 79 ( 7 7  23 48.3 23 <:7 S 23 50.3 27 < 1 1
Mental (8.24) ' (7.91) ' (7.10)
Health 
Score
SF36 24 52.8 79 < 7 4  23 50.2 23 23 51.1 27 ^ 1 7
Mental (9.31) ' (8.98) ' (7.26)
Component 
Summary
SF36 24 34.2 79 31.1 23 37.8 23 36.6 23 39.5 27 38.5
Physical (8.22) (10.86) (10.00) (9.33)
Component
Summary_____________________________________________________ ___________________________
Table 19 Q uality of life as m easured a t screening and again on Day 36 (high dose), results 
displayed per trea tm en t group
(8.27) (8.46) (7.15)
(10.01) (8.77) (7.96)
11
S F -j6  component scores and summary scores
Figure 23 A graph displaying the change in the SF-36 scores from screening to last study day. 
The bars represent pregabalin, duloxetine, and amitriptyline (an increase in the score indicates 
improved quality of life, whilst a decrease indicates poorer quality of life).
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12.3. Cognitive function and psychom otor perform ance
Cognitive function was measured using a battery of computerised and ‘paper and 
pencil’ tests. These measurements were used to assess varying cognitive domains 
including attention, reaction time, memory and psychomotor speed. Testing was 
conducted four times on Day 8, Day 22, and Day 36 with thorough training on Day 7, 
and re-familiarisation on Day 21 and Day 35.
Placebo Pregabalin Duloxetine Amitriptyline
L ow  dose High dose L ow  dose High dose Low  dose High dose
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
N Mean
(SD)
•cop Valid 66 785.2 19 738.1 17 721.8 21 727.3 21 714.5 24 730.9 22 701.3
sponses 
action Time
(123.72) (125.13) (107.07) (81.11) (90.21) (113.56) (103.04)
T  Mean 74 15.9 21 16.8 19 19.6 23 15.1 23 15.0 25 16.1 23 16.7
viation (10.19) (12.36) (14.44) (9.95) (10.52) (8.83) (11.45)
;mberg 74 863.6 21 768.3 19 795.6 23 860.8 23 829.7 25 800.2 23 771.4
;mory
action Time
(154.94) (140.31) (179.06) (121.68) (121.31) (144.13) (136.53)
erall
'F Mean 73 27.4 21 27.4 19 26.9 23 30.0 23 30.1 24 26.8 22 27.2
reshold
;quency
(2.69) (2.05) (1.95) (3.11) (3.27) (2.41) (2.11)
IT 74 502.3 21 460.7 19 478.0 23 446.4 23 426.6 25 471.5 23 448.3
cognition  
action Time
(183.13) (108.74) (109.24) (102.29) (88.26) (113.99) (97.77)
LT Motor 74 328.7 21 308.0 19 302.8 23 306.0 23 299.9 25 302.4 23 302.0
action Time (73.90) (91.26) (73.26) (74.37) (72.53) (62.38) (60.71)
IT Total 74 831.0 21 768.6 19 780.8 23 752.4 23 726.5 25 773.9 23 750.3
action Time 217.33 176.26 147.36 129.18 120.01 145.74 130.71
1ST Total 74 29.4 21 33.1 19 32.8 23 32.2 23 32.9 24 31.1 23 32.5
mber o f  
sponses
(8.48) (7.69) (7.13) (8.43) (8.86) (10 .11) (11.09)
1ST Number 74 28.5 21 32.1 19 32.1 23 31.3 23 32.0 24 29.9 23 31.3
Correct
sponses
(8.71) (8.14) (7.37) (8.64) (8.89) (10.35) (11 .45)
mediate Word 74 6.9 21 7.5 19 7.3 23 7.5 23 7.6 25 6.0 23 5.4
call
(2.97) (2.57) (2.54) (3.25) (3.31) (2.84) (2.62)
layed Word 74 3.2 21 3.4 19 3.2 23 4.3 23 4.1 25 2.5 23 2.3
call (2.84) (2.54) (2.68) (3.02) (3.05) (2.64) (2.30)
Table 20 Mean scores for each cognitive test at baseline (placebo), and at each visit by treatment group 
(there is less data for the stroop variable as some of the patients were colour-blind).
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12.3.1. CTT mean deviation
For tracking mean deviation there was a significant treatment by time effect 
(F (4,68.85) = 4.55, P < 0.01).
Patients on pregabalin had a significantly higher CTT tracking score (mean deviation), 
when compared to those on duloxetine. This treatment by time effect was significant 
when comparing pregabalin with duloxetine, from visit 1 (baseline) to visit 2 (low 
dose) (Cohen’s d 0.96, P < 0.01), from visit 1 to visit 3 (high dose) (Cohen’s d 1.07, P 
< 0.01), and from visit 1 to the combination of visit 2 and 3 
(Cohen’s d 1.14, P < .0001)
The treatment by time effect was also significant when comparing pregabalin with 
amitriptyline, with patients on pregabalin having a higher CTT tracking score. This 
was significant when comparing pregabalin with amitriptyline, from visit 1 to visit 2 
(Cohen’s d 0.64, P < 0.05), from visit 1 to visit 3 (Cohen’s d 0.69, P < 0.05) and from 
visit 1 to the combination of visit 2 and 3 (Cohen’s d 0.75, P < 0.01).
There was no significant treatment by time effect when comparing duloxetine and 
amitriptyline, see Figure 24.
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Figure 24 A figure displaying the CTT mean deviation for all three treatment groups at baseline, 
low-dose, and high-dose.
Pregabalin (♦), duloxetine (■), amitriptyline (A), data points represent mean CTT mean 
deviation scores, whilst the error bars display the SE, * = pregabalin significant compared to 
amitriptyline, **** = pregabalin significant compared to duloxetine.
12.3.2. STM reaction time
For the STM reaction time there was no statistically significant treatment or treatment 
by time effect.
There was a significant visit effect (F (2,6i oo) = 23.54, P < .0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a reduced reaction time 
(Cohen’s d 0.94, P < 0.001, Cohen’s d 0.99, P < 0.001, and Cohen’s d 1.04, P < .0001 
respectively). From visit 1 to visit 3 (high dose) patients in the duloxetine group and 
amitriptyline group had a reduced reaction time (Cohen’s d 0.95, P < 0.001 and 
Cohen’s d 0.84, P < 0.01 respectively), see Figure 25.
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placebo (Day 8 ) low - dose (Day 22) high - dose (Day 36)
F igure 25 A figure displaying the STM reaction tim e for all th ree trea tm en t groups a t baseline, 
low-dose, and high-dose.
P regabalin  (♦ ) ,  duloxetine (H ), am itriptyline (A ), data points represen t m ean STM reaction 
tim e, whilst the e rro r  bars display the SE.
12.3.3. DSST total number of responses
For the DSST total number of responses there was no statistically significant 
treatment or treatment by time effect.
There was a significant visit effect (F (2,60.60) = 14.84, P < .0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
and amitriptyline group had an increased total number of responses (Cohen’s d 0.90, P 
< 0.001, and Cohen’s d 0.92, P < 0.001 respectively). From visit I to visit 3 (high 
dose) patients in the duloxetine group and amitriptyline group had an increased total 
number of responses (Cohen’s d 0.92, P < 0.001 and Cohen’s d 1.05, P < 0.0001 
respectively). See Figure 26.
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low - dose (Day 22) high - dose (Day 36)placebo (Day 8 )
Figure 26 A figure displaying the total num ber of DSST responses for all th ree trea tm en t groups 
at baseline, low-dose, and high-dose.
Pregabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data  points represen t mean DSST total 
num ber of responses, whilst the e rro r  bars display the SE.
12.3.4. DSST number of correct responses
For the DSST number of correct responses there was no statistically significant 
treatment or treatment by time effect.
There was a significant visit effect (F (2,61.65) = 14.04, P < .0001).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
and amitriptyline group had an increased number of correct responses (Cohen’s d 0.83, 
P < 0.01, and Cohen’s d 0.88, P < 0.001 respectively). From visit 1 to visit 3 (high 
dose) patients in the duloxetine group and amitriptyline group had an increased 
number of correct responses (Cohen’s d 0.87, P < 0.01 and Cohen’s d 1.05, P <
0.0001 respectively). See Figure 27.
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Figure 27 A figure displaying the total num ber of correct DSST responses for all th ree  trea tm en t 
groups a t baseline, low-dose, and high-dose.
P regabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t mean DSST num ber of 
correct responses, whilst the e rro r  bars display the SE.
12.3.5. CFF Mean Threshold
For CFF mean threshold frequency there was a significant treatment by time effect 
(F (4.73 83)=H.47,P<.000l).
Patients on duloxetine had a higher CFF mean threshold frequency as compared to 
pregabalin. This treatment by time effect was significant when comparing duloxetine 
with pregabalin, from visit 1 (placebo baseline) to visit 2 (low dose)
(Cohen’s d 1.29, P < .0001), from visit 1 to visit 3 (high dose)
(Cohen’s d 1.45, P < .0001), and from visit 1 to the combination of visit 2 and 3 
(Cohen’s d 1.46, P < .0001 )
The treatment by time effect was also significant when comparing duloxetine with 
amitriptyline, with patients on duloxetine having a higher CFF mean threshold 
frequency. This was significant when comparing duloxetine with amitriptyline, from
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visit 1 (placebo baseline) to visit 2 (low dose) (Cohen’s d 1.45, P < .0001), from visit 
1 to visit 3 (high dose) (Cohen’s d 1.40, P < .0001) and from visit 1 to the 
combination of visit 2 and 3 (Cohen’s d 1.51, P < .0001).
There were no significant differences between pregabalin and amitriptyline, see 
Figure 28
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placebo (Day 8 ) low - dose (Day 22) high - dose (Day 36)
F igure 28 A figure displaying the mean CFF threshold frequency for all th ree trea tm en t groups 
a t baseline, low-dose, and high-dose.
P regabalin (♦ ) ,  duloxetine (■ ) , am itrip ty line (A ), data points represen t m ean CFF mean 
threshold frequency, whilst the e rro r  bars display the SE. **** = duloxetine significant as 
com pared to pregabalin  and am itriptyline
12.3.6. CRT recognition reaction time
For CRT recognition reaction time (RRT) there was a significant treatment by time 
effect (F (4,46.14) = 4.70, P < 0.01).
Patients on duloxetine had a faster RRT as compared to pregabalin. This treatment by 
time effect was significant when comparing duloxetine with pregabalin, from visit I 
(placebo baseline) to visit 2 (low dose) (Cohen’s d 0.79, P < 0.01), from visit 1 to visit
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3 (high dose) (Cohen’s d 1.18, P < .0001), and from visit 1 to the combination of visit
2 and 3 (Cohen’s d 1.05, P < 0.01)
The treatment by time effect was also significant when comparing amitriptyline with 
pregabalin, with patients on amitriptyline having a faster RRT. This was only 
significant when comparing amitriptyline with pregabalin, from visit 1 (placebo 
baseline) to visit 3 (high dose) (Cohen’s d 0.69, P < 0.05) and from visit 1 to the
combination of visit 2 and 3 (Cohen’s d 1.05, P < 0.05).
There were no significant differences between duloxetine and amitriptyline, see 
Figure 29.
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Figure 29 A figure displaying the CR T recognition reaction tim e for all th ree trea tm en t groups at 
baseline, low-dose, and high-dose.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A) ,  data points represent mean C R T recognition 
reaction tim e, whilst the e rro r  bars display the SE. * = am itrip ty line significant com pared to 
pregabalin , ** duloxetine significant com pared to pregabalin , **** duloxetine significant 
com pared to pregabalin
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12.3.7. CRT motor reaction time
For CRT motor reaction time (TRT) there was no significant treatment or treatment 
by time effect.
There was a significant visit effect (F (2,52.12) = 11.02, P < 0.0001 ).
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the duloxetine group 
and amitriptyline group had a reduced motor reaction time (Cohen’s d 0.91, P < 0.01 
and Cohen’s d 0.86, P < 0.01 respectively). From visit 1 to visit 3 (high dose) patients 
in the duloxetine group and amitriptyline group had a reduced motor reaction time 
(Cohen’s d 1.05, P < 0.01 and Cohen’s d 0.73, P < 0.05 respectively). See Figure 30.
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Figure 30 A figure displaying the C R T m otor reaction tim e for all th ree trea tm en t groups at 
baseline, low-dose, and high-dose.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A) ,  data points represent mean C R T m otor 
reaction tim e, whilst the e rro r  bars display the SE.
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12.3.8. CRT total reaction time
For CRT total reaction time (TRT) there was a significant treatment by time effect 
(F (4,48.87) = 3.38, P < 0.05).
Patients on duloxetine had a faster TRT as compared to pregabalin. This treatment by 
time effect was significant when comparing duloxetine with pregabalin, from visit 1 
(placebo baseline) to visit 2 (low dose) (Cohen’s d 0.70, P < 0.05), from visit 1 to visit 
3 (high dose) (Cohen’s d 1.12, P < 0.001), and from visit 1 to the combination of visit 
2 and 3 (Cohen’s d 0.99, P < 0.01)
The treatment by time effect was also significant when comparing amitriptyline with 
pregabalin, with patients on amitriptyline having a faster TRT. This was only 
significant when comparing amitriptyline with pregabalin, from visit 1 (placebo 
baseline) to visit 3 (high dose) (Cohen’s d 0.61, P < 0.05).
There were no significant differences between duloxetine and amitriptyline. See 
Figure 31.
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Figure 31 A figure displaying the CR T total reaction tim e for all th ree trea tm en t groups a t 
baseline, low-dose, and high-dose.
Pregabalin (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t m ean CR T to ta l reaction 
time, whilst the e rro r  bars display the SE. * = duloxetine significant as com pared to pregabalin , + 
= am itrip ty line significant com pared to pregabalin , **** = duloxetine significant as com pared to 
pregabalin
12.3.9. Immediate word recall
Figure 32 displays the number of eorreet words immediately recalled after 
memorising the twenty words word-list. There were no statistically significant 
differences between treatments or over time.
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dose (Day 36)low - dose (Day 22)placebo (Day 8)
Figure 32 A figure displaying the num ber of w ords correctly recalled a t the im m ediate recall 
point, for all th ree  trea tm en t groups a t baseline, low-dose, and high-dose.
Pregabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data  points represent m ean num ber of w ords 
recalled correctly a t the im m ediate recall point, whilst the e rro r  bars display the SE.
12.3.10. Delayed word recall
Figure 33 displays the number of words correctly recalled at the delayed point of 
cognitive testing. As with the immediate recall data there were no statistically 
significant differences between treatments or over time.
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Figure 33 A figure displaying the num ber of w ords correctly recalled a t the delayed recall point, 
for all th ree trea tm en t groups a t baseline, low-dose, and  high-dose.
P regabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t m ean num ber of w ords 
recalled correctly  a t the delayed recall point, whilst the e rro r  bars display the SE.
12.3.11. Stroop valid responses reaction time
For Stroop valid responses reaction time there was no significant treatment or 
treatment by time effect.
There was a significant visit effect (F (2,56.24) = 36.15, P <.0001)
From visit 1 (placebo baseline) to visit 2 (low dose), patients in the pregabalin group, 
duloxetine group, and amitriptyline group had a reduced (therefore faster) reaction 
time (Cohen’s d 0.71, P < 0.01, Cohen’s d 1.57, P <.0001, and Cohen’s d 
1.37, P <.0001 respectively). From visit 1 to visit 3 (high dose) patients in the 
pregabalin group, duloxetine group, and amitriptyline group had a reduced reaction 
time (Cohen’s d 0.68, P < 0.05, Cohen’s d 1.59, P <.0001, and Cohen’s d 1.63,
P <.0001 respectively). See Figure 34.
125
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Figure 34 A graph displaying the reaction tim e for valid responses on the stroop task  for all 
treatm ents a t baseline, low-dose, and high-dose.
P regabalin  (♦ ) ,  duloxetine (■ ) , am itriptyline (A ), data points represen t mean num ber of w ords 
recalled correctly  a t the delayed recall point, whilst the e rro r  bars display the SE.
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13. Summary of the pharmacodynamic results
When looking at the pharmacodynamic results, there was a significant visit effect for 
the BPI severity score, with all three treatment groups achieving a significant 
reduction in BPI severity scores from baseline to low dose. From baseline to high 
dose this visit effect only remained for the duloxetine group. For the four scores 
which comprise the BPI severity score, worst pain, least pain, average pain, and 
current pain there were similar visit effects.
There was also a significant visit effect for the BPI interference score, with patients in 
the duloxetine group reporting reduced interference by pain from baseline to low dose 
and from baseline to high dose. Further significant visit effects were observed for the 
seven scores which comprise the BPI interference score, of note was the interference 
by pain on sleep score, where there was a significant visit effect for all three groups 
from baseline to low dose and from baseline to high dose.
For the VAS score there was also a significant visit effect which was the same as the 
BPI severity score.
There were very few significant differences for the quality of life measurement from 
baseline to high dose. There was one visit effect for the role physical component score, 
with patients in the pregabalin group reporting a poorer score on this component over 
the duration of the study. The role physical component score measures how quality of 
life is being affected in physical aspects of an individual’s daily life.
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Cognitive function was assessed during the study and analysed in relation to 
pharmacological treatment.
13.1. Sensorimotor co-ordination
For the variable CTT mean deviation, there was a significant treatment by time effect, 
with patients who received pregabalin recording a significantly higher CTT tracking 
score (mean deviation) as compared to both duloxetine and amitriptyline. This 
suggests that pregabalin impairs Sensorimotor co-ordination and divided attention.
There was a significant visit effect for the STM reaction time variable, with patients in 
all three groups achieving a reduced reaction time from baseline to low dose. From 
baseline to high dose this visit effect was observed in the duloxetine and amitriptyline 
groups. This improved performance could be attributed to practice effects rather than 
actual improvement over time.
13.2. CNS arousal and information processing
When looking at the DSST total number of responses and DSST number of correct 
responses there was a significant visit effect. From both baseline to low dose and 
baseline to high dose, patients in the duloxetine and amitriptyline group showed an 
increased total number of responses and increased number of correct responses. 
However with DSST in particular it’s widely reported that practice effects are difficult 
to extinguish and this result is likely to be a practice effect (Hinton-Bayre, 2005).
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There was a significant treatment by time effect for the CFF mean threshold variable, 
with patients in the duloxetine group recording higher CFF mean threshold frequency 
scores as compared to pregabalin at all visit combinations. This treatment by time 
effect was also significant when comparing duloxetine with amitriptyline, with again 
patients in the duloxetine group achieving a higher score at all visit combinations.
This significant treatment by time effect is suggestive of improved information 
processing by the central nervous system. The CFF task has been shown to be resilient 
to practice effects (Parkin et al., 1997) so this effect is likely to be as a result of the 
pharmacological treatments.
When looking at the stroop valid responses reaction time variable there was a 
significant visit effect with all three groups recording a faster reaction time from 
baseline to low dose and from baseline to high dose.
13.3. Psychomotor Speed
For the CRT recognition reaction time variable there was a significant treatment by 
time effect with patients on duloxetine and amitriptyline recording faster RRT scores 
as compared to pregabalin. For duloxetine this was significant for all visit 
combinations, whereas for amitriptyline versus pregabalin this was significant from 
baseline to low dose and from baseline to the combination of low dose and high dose.
When looking at the CRT total reaction time variable there was a similar significant 
treatment by time effect to the effect seen for RRT. There were faster TRT times for 
the duloxetine and amitriptyline groups as compared to pregabalin. When comparing 
duloxetine with pregabalin this was significant for all visit combinations, whilst for 
amitriptyline and pregabalin this was only significant when comparing baseline with 
high dose.
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There was a significant visit effect for the variable CRT motor reaction time with 
patients in the duloxetine and amitriptyline group recording a reduced MRT from 
baseline to low dose and from baseline to high dose. With this effect being a visit 
effect rather than a treatment effect, it is more likely to be due to practice effects.
13.4. Learning and memory
There were no significant differences for either of the word recall variables, this is of 
interest as amitriptyline is known to impair memory (Spring et al., 1992).
14. Discussion of the pharmacodynamic results
Whilst there were reductions in subjective pain scores, none of the three treatments 
were superior to any other in reducing the pain associated with painful DPN in this 
study population.
There was also no improvement in QoL scores after this period of pharmacological 
treatment.
When looking at the cognitive function variables there were a number of changes, 
with differences being significant either as a treatment by time effect or a significant 
visit effect.
The significant treatment by time effects were seen when comparing pregabalin with 
duloxetine, and pregabalin with amitriptyline, with patients receiving pregabalin 
recording a higher (impaired) CTT tracking score. This is indicative of pregabalin 
having a negative impact on this variable as compared to with duloxetine and
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amitriptyline over time. This finding may be consistent with its known 
pharmacological action on CNS GAB A neurotransmission.
There was also a significant treatment by time effect for the variable CFF mean 
threshold. Patients on duloxetine had a higher CFF mean threshold score as compared 
to pregabalin and amitriptyline. This higher score indicates an improvement by 
duloxetine over time as compared to the other two treatments. This may relate to its 
predominant action via 5-hydroxytryptamine neurotransmission.
The variable CRT recognition reaction time was also seen to have a significant 
treatment by time effect, with patients on duloxetine recording a faster RRT as 
compared with pregabalin. When comparing amitriptyline with pregabalin from 
baseline to high dose, patients on amitriptyline had a faster RRT. This suggests that 
both duloxetine and amitriptyline improved RRT but when looking at the graph for 
this variable it seems that the pregabalin patients started with a slower RRT at 
baseline, so perhaps this should be viewed with caution. The same significant 
treatment by time effect was also seen for the variable CRT total reaction time but 
with the slower baseline score for pregabalin this should also be viewed cautiously.
There were significant visit effects for the variables STM reaction time, DSST total 
number of responses, DSST number of correct responses, CRT motor reaction time, 
and stroop valid responses time.
Whilst these significant visit effects are of interest they cannot be attributed to the 
pharmacological treatment and will be discussed further in the main discussion.
One noticeable aspect of the pharmacodynamic results is the lack of an effect by 
amitriptyline. On visual inspection of the graphs for immediate and delayed word
131
recall, amitriptyline appears to be exerting a negative effect on memory consistent 
with its anticholinergic properties, but without any significant results this can only be 
speculative.
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Chapter 5; Discussion
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15. Discussion 
15.1. Pain
Chronic pain associated with diabetic peripheral neuropathy (DPN) is often hard to 
treat, and untreated pain is distressing to patients with negative effects on quality of 
life and sleep. When selecting the most appropriate treatment for a patient it is also 
important to consider that pharmacological treatments for pain may have behavioural 
toxicity resulting in undesirable side effects including impairment of cognitive 
function which might act to further reduce, rather than improve, quality of life.
This thesis investigated the pain relieving properties of three analgesic drugs with 
differing mechanisms of action (pregabalin, duloxetine, and amitriptyline) in patients 
with painful DPN. In addition, their effects on quality of life (QoL), and on 
subjective and objective measures of sleep were compared, together with their effects 
on cognitive function.
15.1.1. Baseline Pain scores
The results showed that in comparison with other studies in the literature (see Table 
21), patients in this thesis study had a lower mean baseline pain score as measured by 
the Brief Pain Inventory (BPI). One study by Hoffman et al., (2009) was conducted 
over 19 countries with baseline data collected for 399 -  401 patients with painful 
DPN (missing data values causes the N range). The mean BPI severity score was 6.6 
and the mean BPI interference score was 5.2. Mean ages for this study were reported 
across three regions as being 56.6, 59.4, and 55.9. Another study by Armstrong et al., 
(2007) reported baseline BPI scores for 399 patients with painful DPN. The BPI 
average pain score was 4.1 (compared to 3.6 in the thesis study) and the patients had a
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mean age of 60.1. Baseline BPI scores were also recorded by Swislocki et al., (2009), 
for 449 patients with painful DPN with a mean age of 59.9 and a mean BPI average 
pain score of 5.3. A smaller study was conducted by York et al., (2009), where pain 
scores were measured for 55 patients with painful DPN. In the treatment group there 
was a mean BPI severity score of 4.9 and a mean BPI interference score of 4.7, and in 
the control group there was a mean BPI severity score of 5.1 and a mean BPI 
interference score of 5.5. The patients had a mean age of 59.7.
One of the main differences between this current thesis study and other studies, 
however, was the selection of inclusion criteria in relation to pain. In the thesis study, 
patients were required to have a score of 12 or above on the LANSS, whereas in the 
Hoffman et al (2009) study, inclusion criteria were a score of at least 40mm on the 
VAS from the McGill pain questionnaire and an average pain score of at least 4 (from 
0-10) in the week prior to baseline. In the Armstrong et al., (2007) study patients were 
required to have a score > 4 on average pain severity, whilst in the Swislocki et al., 
(2009) study patients were required to report a score of > 3 (from 0 -  10) on average 
pain in their feet. In the York and Gordon study (2009) the McGill short form pain 
questionnaire was used and one of the inclusion criteria was a score of > 3 on question 
3 of this questionnaire. This question measures present pain intensity and patients are 
required to rate their present pain from no pain = 0 to excruciating = 5.
Another difference was that the study outlined here was a relatively small (n=83) 
clinical trial whereas other studies have been larger scale, multi-centre trials (n = 55 -  
449), with some studies spanning continents. The mean age was also slightly higher 
at 65.1.
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15.1.2. Pharmacological treatment of painful DPN
There have been few comparisons of the drugs either licensed for the treatment of 
pain associated with painful DPN, or recommended by the British national formulary 
(BNP) (Quilici, Chancellor et al. 2009). The primary objective of this study was to 
compare the analgesic properties of pregabalin, duloxetine, and amitriptyline to 
investigate if any of the drugs was superior in reducing pain associated with painful 
DPN.
Analysis of the pharmacodynamic data showed that none of the three drug treatments 
was superior to another in reducing pain as measured by the BPI and the short-form 
McGill VAS.
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15.1.3. Pharmacological treatment and DPN
Several studies have investigated the efficacy of pharmacological treatments at 
reducing neuropathic pain. A previous study by Dallocchio et al (2000) compared 
gabapentin with amitriptyline in reducing pain in patients with painful DPN (mean 
age 71 years). Over a period of twelve weeks, gabapentin was found to be superior in 
comparison to amitriptyline. Gabapentin and amitriptyline were also compared by 
Morello et al., (1999), where the age group was similar to the current thesis study, and 
they found no significant differences between the drugs in reducing painful DPN.
A direct comparison study between amitriptyline and pregabalin has previously been 
undertaken by (Bansal, Bhansali et al. 2009). There were 51 patients and the study 
was conducted over a period of 5 weeks for each drug, with a 3 week wash-out period 
between the drugs. They reported no significant differences between the drugs and 
suggested that 150mg of pregabalin twice daily may be the best option when looking 
at tolerance and side effects.
This thesis study data adds to the literature that there was no significant difference 
between amitriptyline and other drugs used to alleviate pain associated with DPN.
With respect to duloxetine treatment, previous studies have generally compared 
duloxetine with placebo rather than with active comparator.
A meta-analysis by Quilici et al., (2009) was conducted to compare studies that have 
included pregabalin, duloxetine and amitriptyline. Unfortunately none of the 
amitriptyline studies met their meta-analysis inclusion criteria and so only duloxetine 
and pregabalin were compared in the meta-analysis. When comparing duloxetine with 
pregabalin there was no evidence of a significant difference in 24hourpain scores. For
138
patient impression of global change scores, pregabalin was superior, whilst for 
dizziness scores duloxetine was superior. From this meta-analysis they concluded that 
duloxetine provided an important treatment option for painful DPN.
15.1.4. BPI Severity
When looking at post hoc analysis of the BPI severity data (in the thesis study) it was 
observed that there was a significant change over time in all three treatment groups, 
with all three groups reporting a reduction in pain severity from baseline (placebo) to 
low dose. From baseline to high dose there was only a reduction in pain severity for 
patients in the duloxetine treatment group. This change over time could indicate that 
only duloxetine was beneficial at the higher dose but with no significant treatment 
effect reported this conclusion cannot be supported by the data presented here.
It is difficult to directly compare the current study with others previously reported as 
in many cases there are substantial differences in study design. In the Dallocchio et 
al., (2000) study, measurement of pain was with a pain intensity scale with patients 
rating from 0-4. In that study also patients were titrated from 30mg of amitriptyline to 
a maximum of 90mg over a period of 4 weeks and then remained at a dose tolerable to 
the individual for the remainder of the study, (8 weeks). The patients found 
amitriptyline to be effective for the duration of the study. Amitriptyline has also been 
found to be effective in reducing pain over a 12 week study, Morello et al., (1999), 
with patients receiving variable amitriptyline doses ranging from 12.5mg to 75mg. In 
the current thesis study patients were titrated from placebo to amitriptyline 50 mg and 
to 75 mg. There was evidence of improved pain score from the placebo baseline to
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amitriptyline 50 mg but no further significant reduction in pain when titrated up to the 
75 mg dose.
Duloxetine has also previously been shown to significantly reduce pain as measured 
by a 24 hour pain score from 0-10 over a twelve week period, as compared with 
placebo. This was investigated by Goldstein et al., (2005), 457 patients participated 
and received 20mg, 60mg, 120mg of duloxetine or placebo daily. Over a twelve week 
period 60mg or 120mg of duloxetine was found to be superior to placebo in reducing 
a 24 hour average pain score by 50%. In the current thesis study patients in the 
duloxetine group did demonstrate a significant reduction in pain over time, with a 
significant reduction in pain at the 60mg dose (27% decrease as compared to baseline) 
and 120mg dose (38% decrease as compared to baseline).
More variable results have been found in studies with pregabalin. In some studies 
pain scores have been found to be reduced significantly by 300 mg pregabalin even 
after just one week of treatment, (Rosenstock et al., 2004), whereas other studies have 
only shown a significant effect at 600 mg and after at least two weeks of treatment 
(Tolle et al., 2008, Portenoy et al., 2005). The current thesis demonstrated that 
patients in the pregabalin group did have a significant reduction in pain severity (26%) 
from visit 1 (placebo baseline) to visit 2 (low dose, 300 mg pregabalin), but that there 
was no further change when patients titrated to the higher, 600 mg, dose.
15.1.5. BPI Interference
Overall for the BPI interference score, a measure of how the patient’s pain interferes 
with everyday activities, there was only a significant reduction in pain interference in 
the duloxetine treated group over time from baseline (placebo) to low dose, and from 
baseline (placebo) to high dose. Although as there was no significant difference
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between any of the treatments on pain interference, these changes over time in the 
duloxetine group must be treated with caution. In terms of individual interference 
components there was consistent evidence that duloxetine improved pain interference 
on a range of measures including mood, general activity, walking ability and 
enjoyment of life (although these improvements are a visit effect rather than a direct 
treatment effect). Although these changes were over time rather than a direct drug 
effect it is interesting that the duloxetine group saw an improvement in the pain 
interference on mood question but not the amitriptyline group when both duloxetine 
and amitriptyline were primarily developed as antidepressants.
There was evidence of a significant reduction in all groups for interference by pain on 
sleep which would be expected to further accentuate the benefit to patients in reducing 
pain, and would be expected to have a positive effect on aspects of daily life as well 
as the sensation of pain relief.
BPI interference has been previously measured when assessing the analgesic efficacy 
of duloxetine in patients with painful DPN (Armstrong et al., 2007). In the Armstrong 
study patients received duloxetine 20 mg, 60 mg, 120 mg, or placebo. Results were 
pooled from three 12 week studies with a total of 1139 participants and both 
duloxetine 60mg and 120mg were found to significantly improve BPI interference 
scores as compared to placebo. Although the thesis data should be viewed cautiously, 
it seems to support previous research with equivalent doses of duloxetine reducing 
pain interference as measured by the BPI. It should be noted however that there was 
no significant difference between any of the treatments on pain interference.
The primary objective of this study was to investigate the pain relieving properties of 
these three different drugs which belong in different classes of drug classification.
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Based on this primary objective and previous research, the study hypothesis that, one 
or more of the drugs will be superior in relieving pain, was formulated. From these 
thesis results this hypothesis cannot be supported as there was no significant 
superiority by any of the drugs in relieving pain associated with painful DPN.
Although all three treatments appeared effective at reducing neuropathic pain one 
further consideration is cost effectiveness. There is currently a substantial cost 
difference between pregabalin and duloxetine compared to amitriptyline. Considering 
that for all lower doses there was a reduction over time in pain severity scores, it is 
possible to speculate that any of these three drugs could be prescribed in an attempt to 
alleviate the chronic pain associated with diabetic peripheral neuropathy. However 
when prescribing drugs it is important to keep in mind undesirable side effects which 
could impact on quality of life, cognitive function, and sleep. It is also important to 
take into consideration the safety profiles of these drugs, especially in this patient 
population which is often older adult, which can make selecting a suitable prescription 
more challenging.
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15.2. Q uality o f life
Baseline (screening) scores for the current study were compared with previous 
literature in patients with painful DPN. Previous studies were conducted by York et 
al., (2009) with baseline SF-36 scores for 55 subjects (mean age of 59.7). They 
reported a mean bodily pain score of 34.2 for the treatment group, and 36.1 for the 
control group compared with 39.2 for the thesis study, indicating a slightly superior 
quality of life for the patients in the thesis study. Another study was conducted by 
Swislocki et al., (2009) with baseline scores for 121 painful DPN patients (mean age 
64.4). There were two groups for this study; in the control group there was a physical 
component summary score of 31.4 and a mental component score of 43.8, in the 
treatment group there was a physical component summary score of 34.9 and for the 
mental component summary score 43.7, compared to the thesis study with a physical 
component summary score of 37.1 and a mental component summary score of 51.4, 
again suggestive that the patients in the thesis study had an improved quality of life as 
compared to the patients in the Swislocki et al., (2009) study. Baseline SF-36 scores 
were also available for 270 painful DPN patients with a mean age of 60.1 (Armstrong 
et al., 2007). Conversely as compared to patients in the thesis study, on seven out of 
the 8 component scores, patients in the Armstrong study had a superior quality of life, 
see Table 22.
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15.2.1. Baseline quality of life and pain
As part of the secondary objective of this thesis research, baseline scores in this 
patient group were investigated. Regression analysis between the baseline BPI scores 
and baseline (screening) SF-36 scores resulted in negative associations between the 
variables suggesting that as pain severity increased quality of life was reduced.
The BPI severity score correlated with the majority of the SF-36 components apart 
from the role physical, general health, and role emotional components. The BPI 
severity score correlated with both the mental component summary score and the 
physical component summary score.
When looking further at the four scores that were combined to produce the severity 
score (worst pain, least pain, average pain, and current pain), the scores also 
negatively correlated with the SF-36 scores in a similar manner to the overall severity 
score. Even the least pain score was found to correlate with the SF-36 score, which 
alluded to just how much the pain experienced by these patients negatively impacted 
on aspects of quality of life.
In addition, the BPI interference score negatively correlated with all of the SF-36 
component scores and with both of the summary scores. In some cases these 
correlations were highly significant (p <0.0001). When looking further at the 
individual questions that were combined to produce the interference score, most of 
them correlated with the SF-36 component scores and summary scores. Again these 
negative associations indicated just how much pain interfered with quality of life in 
these patients and why successful pain management would be so beneficial.
The visual analogue scale produced similar correlations, with negative associations 
between the VAS and the majority of the SF-36 scores and both of the summary
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scores. These results provide further evidence that pain and quality of life are 
negatively associated with each other and support previous research that suggests that 
painful DPN has a negative impact on quality of life (Benbow, Wallymahmed et al. 
1998; Galer, Gianas et al. 2000; Turk and Melzack 2001; Smith and Nicholson 2007).
15.2.2. Quality of life and pharmacological treatment
There was no significant difference of any of the treatments on quality of life as 
assessed by the SF-36. No drug was identified as being superior or inferior to another. 
Although quality of life component scores reduced from screening to the last day of 
the study (suggesting a worsening of quality of life), the only statistically significant 
change over time was for the pregabalin group for the role physical component score 
suggesting that for the pregabalin treated group there was a worsening of physical 
aspects of quality of life.
With no significant changes in quality of life scores the study hypothesis that with 
reduced pain scores, quality of life scores will increase, must be rejected, especially as 
the (non-significant) change that was seen was in the opposite direction to what was 
originally expected.
The SF-36 is a quality of life measure that gives a complete health profile on a 
number of dimensions. It has been previously used to investigate QoL in patients 
with painful DPN. In an open label extension study by Wernicke et al., (2007), the 
authors reported that duloxetine (60mg BID (twice daily) improved SF-36 scores as 
compared with patients receiving routine care over a 52 week period. Quality of life 
was also measured by Goldstein et al., (2005) in a study where, over a period of 12 
weeks, patients with painful DPN received duloxetine 20 mg, 60mg or 120mg, or 
placebo daily. As compared to placebo, patients receiving 60mg of duloxetine daily
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had a significant improvement in bodily pain and mental health as measured by the 
SF-36, and for patients receiving 120mg there was also significant improvement in 
bodily pain, mental health, and general health perceptions as measured by the SF-36. 
Duloxetine also improved quality of life scores in a study by Armstrong et al., (2007), 
over 12 weeks a total of 1139 participants received duloxetine at 20mg, 60mg, 120mg, 
or placebo. They reported a significant improvement on all SF-36 questions at 60mg 
and 120mg doses as compared to placebo.
Quality of life scores in relation to treatment with pregabalin have also been measured. 
In an 8 week study, Rosenstock et al., (2004) measured SF-36 scores for 146 patients 
randomised either to placebo or pregabalin 300mg per day and a significant increase 
in quality of life score was seen for the SF-36 bodily pain as compared to placebo.
The reason for the difference between quality of life changes in the current study and 
published studies is unclear, however in the current study quality of life was assessed 
over just a five week period where one week involved a placebo run-in and there were 
only two weeks at the higher dose. The SF-36 asks respondents to rate their answers 
in relation to the previous four weeks and therefore it was expected that this timescale 
was suitable for capturing change in the patients by using the SF-36. Future studies 
might consider using a range of quality of life assessments or incorporating a longer 
treatment regime. As the study was originally powered on the BPI pain scores, it is 
also possible that the study wasn’t sufficiently powered to demonstrate changes in 
quality of life.
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15.3. Subjective pain and sleep
There was a good correlation at baseline between subjective measures of pain and 
subjective measures of sleep. These correlations showed that a higher pain score was 
associated with poorer sleep.
When looking at the quality of sleep as recorded daily in a patient diary, all of the 
pain measurements (BPI severity and associated questions, BPI interference and 
associated questions, and the VAS) correlated with the quality of sleep score, 
suggesting that pain was significantly affecting sleep quality. Given that the 
relationship between sleep and pain is complex it is also possible that these patients 
already have poor sleep quality and that this is itself lowering the pain threshold and 
causing subjective pain ratings to increase. The close inter-relationship between pain 
and sleep has been shown previously with evidence that disturbed sleep is linked to a 
lowering of the pain threshold (Chiu, Silman et al. 2005).
Daytime sleepiness levels (as measured by the Karolinska sleepiness scale) were also 
found to correlate significantly with measurements of pain. BPI interference and 
worst pain both correlated with daytime sleepiness levels with results indicating that 
increased worst pain and pain interference were associated with increased daytime 
sleepiness. It has previously been shown that in chronic pain conditions, patients 
complain of increased daytime sleepiness (Roehrs and Roth, 2005). The current study 
supports these observations.
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15.4. Cognitive function
Exploratory analysis revealed that there were no consistent associations between 
baseline pain scores and baseline cognitive function. This was a positive finding as it 
would suggest that for these patients, pain is not exerting a negative impact on 
cognitive function or that the patients have learnt to compensate for any cognitive 
deficits.
Previous research into cognitive function and painful DPN has compared painful DPN 
patients with either individuals with just diabetes or healthy controls. This previous 
research has shown psychomotor efficiency is impacted in these patients with painful 
DPN (Ryan, Williams et al. 1992). Previous research into cognitive function and 
diabetes has found that cognition is affected in diabetics without either neuropathy or 
painful neuropathy (Brands, Biessels et al. 2005; Kodl and Seaquist 2008) Without a 
control group this thesis data cannot be compared to previous studies in regards to 
how cognitive function is effected by painful DPN.
15.4.1. Cognitive function and pharmacological treatment
When prescribing pain drugs it is important to consider possible detrimental effects 
that the psychoactive compounds might have, as there is limited benefit in treating 
pain symptoms if it is at the expense of a patient’s ability to carry out daily tasks.
Part of the primary objective of this thesis research was to investigate the effect of 
these three different drugs on cognitive function. Cognitive function was assessed 
using a battery of computerised and pen and paper tests at baseline (placebo), at low 
dose and at high dose. Analysis of this data showed differing effects of these pain 
drugs on aspects of cognitive function possibly attributable to their differing actions in 
the CNS.
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15.4.1.1. Continuous Tracking Task (CTT)
Analysis showed a treatment by time effect for the CTT mean deviation score.
Patients taking pregabalin had a higher CTT deviation score (impaired performance) 
as compared to duloxetine and amitriptyline. These contrasts were significant when 
comparing baseline (placebo) with low dose, and comparing baseline with high dose, 
and the combination of low dose and high dose compared with the baseline score. 
These data suggest that pregabalin treatment reduced tracking task accuracy, with 
patients having a higher level of deviation away from the target, as compared to 
patients taking duloxetine, or amitriptyline.
Previous research by Hindmarch et al., (2005) assessed 24 healthy subjects who were 
administered 150mg pregabalin TID (three times a day), alprazolam 1 mg TID, or 
placebo TID. They also reported that pregabalin significantly impaired CTT scores as 
compared to placebo. The current study and that by Hindmarch et al (2005) suggest 
that pregabalin may impair divided attention tasks such as tracking ability. Divided 
attention tasks such as continuous tracking are an important indication of potential 
impairment on everyday tasks such as driving ability (Verster, Volkerts et al. 2002). 
This could have serious implications for the patients as cognitive impairment has been 
shown to be linked to accident risk (Kress and Kraft 2005), especially as impairment 
was still evident after four weeks of treatment, with two of those weeks at the higher 
dosage of pregabalin.
So whilst this study supports previous research that the cognitive effects of pregabalin 
can be modest (Salinsky et al., 2010), the fact that the one effect it did have was on 
sensorimotor co-ordination is something to be considered carefully when prescribing. 
This is in line with the summary of product characteristics for pregabalin, which
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advise that patients don’t drive or operate complicated machinery until they are 
familiar with any side effects pregabalin may be causing.
15.4.1.2. Critical Flicker Fusion (CFF)
There was a treatment effect and a treatment by time effect when looking at the effect 
of the drugs for the CFF mean threshold frequency. As compared to pregabalin, 
patients on duloxetine had a higher CFF mean threshold frequency. This was 
significant over time when comparing baseline (placebo) with low dose, baseline with 
high dose, and the combination of low dose and high dose with baseline. As compared 
to amitriptyline, patients on duloxetine had a significantly higher CFF mean threshold 
frequency score, this was also significant over time when comparing visits of the 
study. There was no significant difference between pregabalin and amitriptyline.
When looking at the CFF task, a lowering of the threshold is indicative of a reduction 
in the overall central processing of the central nervous system. These results infer that 
as compared to both pregabalin and amitriptyline, duloxetine increased the CFF mean 
threshold frequency, suggesting an increase in the overall central processing of the 
central nervous system. Previous work on SSRIs have shown an increase mean CFF 
threshold (Schmitt, Riedel et al. 2002). Our data is in agreement with this finding and 
suggests that duloxetine, an SSNRI (similar to the SSRIs) also demonstrates an 
alerting effect in patients with painful DPN and that this effect is sustained even after 
four weeks of treatment. This apparent improvement in CNS arousal and information 
processing is in agreement with previous research which indicates improvement in 
cognition in relation to duloxetine (Herrera-Guzman et al., 2009; Raskin et al., 2007).
It was possible that amitriptyline might impair CFF as previous research by Kerr et al., 
(1996) showed that amitriptyline (25 mg) significantly reduced (impaired) CFF
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threshold as compared to placebo, although this was a very acute dosing study and is 
therefore not entirely comparable, other previous studies have also shown that 
amitriptyline impairs CFF (Fairweather, Kerr et al. 1993; Kinirons, Jackson et al. 
1993), however in this study there were no significant treatment by time effects 
observed for amitriptyline and CFF mean threshold frequency.
15.4.1.3. Choice Reaction time (CRT)
The CRT task can be separated into three measurements, recognition reaction time 
(RRT), motor reaction time (MRT), and total reaction time (TRT). The RRT is the 
time taken to recognise the stimulus and move, the MRT is the time taken to get to the 
light pad, and the TRT is the combination of these two measurements. There was a 
significant treatment by time effect for RRT and TRT, and only a significant change 
over time for the MRT. The CRT task is seen as a measure of psychomotor speed.
For RRT, patients on duloxetine had a significantly quicker reaction time as compared 
to those on pregabalin. This contrast was significant when comparing baseline 
(placebo) to low dose, baseline to high dose, and from baseline to the combination of 
low dose and high dose. Patients on amitriptyline also had a quicker RRT as 
compared to pregabalin. This comparison was significant when comparing baseline 
(placebo) to high dose, but not when comparing baseline to low dose, where the 
amitriptyline score was higher than the pregabalin score. For the TRT, patients on 
duloxetine has a significantly quicker reaction time as compared to pregabalin. Over 
time this was significant when comparing baseline (placebo) to low dose, baseline to 
high dose, and from baseline to the combination of low dose and high dose. There 
was a significant difference between amitriptyline and pregabalin, with a faster 
reaction time for those on amitriptyline, this was only significant when comparing the
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baseline (placebo) with high dose. These results suggest a positive effect of duloxetine 
in increasing (improving) psychomotor speed, but with a lower starting score for the 
pregabalin group these results should be viewed cautiously.
For all other measures of psychomotor performance and cognitive function no 
difference between the three treatments was seen with no indication of significant 
impairment or improvement in performance. There was some indication that in many 
cases performance improved with time. However as the overall treatment effect was 
not significant, it might be that the improvements seen were due instead to practice / 
learning effects on the psychometric tests. Practice effects are often a confounding 
factor in behavioural research. In order to ensure that patients had reached a stable 
level of performance the first day of each residential visit was used as a training or re­
familiarisation day.
One study hypothesis investigated in the current study was that pharmacological 
treatment would be expected to impair cognitive function.
Interestingly the only significant impairment seen with pregabalin was on tracking 
performance and no other cognitive measures were affected. Amitriptyline also 
showed no evidence of consistent cognitive impairment and instead there appeared to 
be a trend towards an improvement in performance on some cognitive tasks. These 
findings were unexpected but demonstrate the importance of fully investigating 
behavioral effects of psychoactive drugs on the patient group to be treated. Duloxetine 
appeared to enhance cognition although whether the ‘alerting’ effect seen led to 
disturbances in sleep is unclear from the results presented.
In summary, the only significant impairment seen with pregabalin was on tracking 
performance and no other cognitive measures were affected. This data supports
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previous research that any cognitive impact by pregabalin is modest (Hindmarch et 
al., 2005; Salinsky et al., 2010) and that antiepileptic drugs as a class of drug have 
mild effects on cognitive function (Martin et al., 2001; Meador et al., 1999; Meador, 
2002; Ortinski, 2004)
Duloxetine was associated with an improvement in cognitive function in this thesis 
research. These findings support previous research which report improvements in 
cognitive function attributable to duloxetine (Herrera-Guzman et al., 2009; Raskin et 
al., 2007).
Previous studies indicated that amitriptyline can be behaviorally toxic (Kerr et al., 
1991; Kerr et al., 1996; Richelson, 1994; Spring et al., 1992) but there was no 
evidence of this in the thesis results.
15.5. Limitations
This thesis study was relatively short in duration for a patient study, and with a lack of 
placebo arm it’s difficult to interpret the data and be certain whether changes seen are 
as a product of time or the pharmacological treatment. For this particular study it was 
felt to be unethical to withdraw these patients from any kind of analgesic treatment to 
create a placebo treatment group to run over a period of five weeks.
As far as statistics and patient numbers are concerned, this thesis data is part of a 
clinical trial and the numbers selected were powered on the BPI, and it is possible that 
the numbers enrolled onto the study were not sufficient to record significant changes 
in both cognitive function and quality of life scores. Further research in this area 
should consider larger numbers of patients as well as a placebo arm.
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The BPI pain scores were relatively low (in relation to other research in this field). 
Patients were recruited using the LANSS (inclusion criteria required a score of 12 or 
above). Future research should consider recruiting using either the BPI or a VAS 
measuring pain.
16. Conclusions and further work
This comparison of three pain drugs used to alleviate pain in painful DPN has 
revealed no significant superiority with either pregabalin, duloxetine, or amitriptyline 
in reducing pain.
With all three treatments resulting in reduced pain scores as measured by using 
subjective measures, this thesis data supports previous research into these drugs which 
report their beneficial pain relieving qualities.
Whilst all three drugs reduced pain, it is important for other factors such as cognitive 
function, quality of life, and sleep to be taken into consideration when prescribing. If a 
drug is found to be behaviourally toxic and limits the patient then any analgesic 
properties would be questionably beneficial.
Baseline correlations between pain and quality of life indicate just how much pain can 
impact on quality of life in this patient group and this thesis data supports previous 
work which reports interference by pain on quality of life. Unfortunately there were 
no significant improvements of quality of life during the study, which may have been 
due to trial length or insufficient power to detect changes in subjective QoL measures.
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There were strong correlations between subjective pain and sleep, highlighting the 
importance of effective pain management in these patients, and adding to previous 
research that pain impacts on sleep quality and daytime sleepiness.
Impact on cognitive function was modest, with pregabalin exerting a negative impact 
on the continuous tracking task, and duloxetine producing an alerting effect on critical 
flicker fusion mean threshold frequency and aspects of choice reaction time. 
Interestingly amitriptyline did not result in any significant negative impairment 
despite it’s widely reported anticholinergic and sedative side effects.
All drugs were considered relatively safe with no consistent impairments in daytime 
performance. The cost of the three treatments is markedly different and therefore 
from the data presented amitriptyline might seem to be the drug of choice.
16.1. Future work
The study did have limitations and these should be addressed in any future work. In 
order to more fully assess whether diabetic complications impact on cognitive decline 
an age and gender matched healthy control group and diabetic only group should be 
included alongside patients with painful DPN. A much larger study population would 
be required and the treatment regime should be extended to at least a 12 week dosing 
period in order to investigate the longer term effects on performance measures. 
Subjective sleep and pain and other quality of life measures should be considered in 
order to try and better understand how improvements in pain, sleep and daytime 
function impact on the patients overall well being. Other questionnaires could also be 
considered for future work including a version of the BPI which is specific to painful 
DPN, and other quality of life measures and depression scales in conjunction with the 
SF-36.
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In addition in many cases it was not possible to elucidate whether changes with time / 
visit were due to the drug treatment administered or just changes with time. In theory, 
the inclusion of a placebo arm might allow this to be better defined, but the ethical 
difficulties inherent in this have already been discussed.
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Appendix 1 Mini Mental State Examination (MMSE)
MINI MENTAL STATE EXAMINATION (MMSE)
Maximu Actual
m Score Score
ORIENTATION:
(1) Ask for the:
year
season
date
(5) [ _ ]
day
month ..........................
(2) Ask for the:
country
county
town/city
(5) [ _ ]
hospital/address
floor
REG ISTRATIO N :
(3) “1 am going to name three objects. After 1 have said them 1
want you to repeat them. Remember what they are because 1
am going to ask you to repeat them again in a few minutes.”
69
“Please repeat these three items for me.”
GRAPE CHAIR POUND
(3) [ _ ]
A T T E N T IO N  A N D  CALCULATION: D _
L _
(4) “Now 1 am going to say a word forwards and I want you to 
spell it backwards.”
R _
0 _
“The word is W 0  R L D”
W _
(5) [ _ ]
RECALL:
(5) Ask the subject to recall the three objects repeated in the 
registration section above (GRAPE, CHAIR, POUND) (3)
[ _ ]
70
LANGUAGE:
(6) Naming: Show the subject a wristwatch and ask what it is.
Repeat for a pencil. (2) [ _ ]
(7) Repetition: Ask the subject to repeat the following
sentence: “NO IFS, ANDS OR BUTS.”
(1) [ _ ]
(8) Follow a three stage command: Give the subject a piece of
plain, blank paper and repeat the command: “TAKE THE
PAPER IN YOUR RIGHT HAND. FOLD THE PAPER IN
HALF. PUT THE PAPER ON THE FLOOR.”
(3) [ _ ]
(9) Reading: Show the subject the piece of paper provided with
the sentence (CLOSE YOUR EYES) on it. Ask the subject to
read it and do what it says.
(1) [ _ ]
(10) Writing: Give the subject the blank page and ask the
subject to write a sentence.
(11) Copying: Present the subject with the intersecting (1) [ _ ]
pentagon diagram provided and ask the subject to copy it
exactly as it is.
171
(30) [ _ ]
TOTAL M M SE  SC O RE
172
LA N G U A G E  Reading 
Read and obey the following
CLOSE
YOUR EYES
173
LANGUAGE Writing
Write a sentence
174
LANGUAGE Copying
Copy the design in the space provided below
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Appendix 2 SF-36 v2
Your Health and Well-Being
This survey asks for your views about your health. This information 
will help keep track of how you feel and how well you are able to do 
your usual activities. Thank you for completing this survey!
For each of the following questions, please tick the one box that best 
describes your answer.
1. In general, would you say your health is:
Excellent Very good Good Fair Poor
▼ ▼ ▼ T T
□ . O : □> □>
2. Compared to one vear ago, how would you rate your health 
in general now?
fuch better Somewhat Somewhat Mueh worse
now than better About the worse now than
one now than one same as now than one one
year ago year ago one year ago year ago year ago
T ▼ ▼ T T
□ . o , □=
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3. The following questions are about activities you might do 
during a typical day. Does vour health now limit you in these 
activities? If so, how much?
Yes, 
limited 
a lot
Yes, 
limited 
a little
No, not 
limited 
at all
Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports.......... ....... □ . ...... ...... O z ..... ....... o ,
Moderate activities, such as moving a table, pushing 
a vaeuum eleaner, bowling, or playing golf.................
T
....... □ . ......
T
...... O : .....
▼
....... o ,
Lifting or carrying groceries.......................................... ....... □ . ...... ...... O : ..... ....... o ,
Climbing several flights of stairs.................................. ....... □ . ...... ...... O : ..... ....o ,
Climbing one flight of stairs.......................................... ....... □ . ...... ...... O : ..... ....... □ .
Bending, kneeling, or stooping..................................... ....... □ . ..... ...... O : ..... ....... o ,
Walking more than a m ile............................................. ........ □ . ..... ...... ............. ....... o ,
Walking several hundred yards.................................... ........ □ . ..... ...... 0 2 ...... ....... o,
Walking one hundred yards........................................... ........ □ . ..... ...... O : ..... ....... Q,
Bathing or dressing yourself......................................... ........ □ . ..... ...... O : ..... ....... o ,
During the past 4 weeks, how much of the time have vou had 
any of the following problems with your work or other regular 
dailv activities as a result of vour phvsical health?
All of Most of Some of A little of None of 
the time the time the time the time the time
▼ T  T  ▼ ▼
Cut down on the amount of 
time you spent on work or 
other aetivities......................
Aecomnlished less than you
Were limited in the kind of
Had difficulty performing the 
the work or other aetivities (for
...□ . ...... ........O : ........... o , .... .......0 4 ........ .....O 3
....O ' .... ........Oz ........ .......O ' ..... .......0 4 ........ .....O 3
...O ' .... ......O : ..... ... o , .... .....0 4 ..... .....O 3
...O ' .... ......Oz..... ... o , .... .......0 4 ........ ....O 3
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5. During the past 4 weeks, how much of the time have you had 
any of the following problems with your work or other regular 
daily activities as a result of anv emotional problems (such as 
feeling depressed or anxious)?
All of Most of Some of A little of None of 
the time the time the time the time the time
Cut down on the amount of 
time you spent on work or 
other aetivities......................
Accomplished less than you 
would like.............................
Did work or other activities
□  . ...... ........ O z ........ ....... O z ........ .......O ' ........ .......O  z
□  . ...... ........ O z ........ .......O z ....... ....... O ' ........ .......O  z
n ....... ........ O z ........ .......O z ....... ........O ' ........ ....... O  z
6. During the past 4 weeks, to what extent has your physical health 
or emotional problems interfered with your normal social 
activities with family, friends, neighbours, or groups?
Not at all Slightly Moderately Quite a bit Extremely
T  T  ▼ ▼ ▼
□. Dz Dz □ . □>
7. How much bodilv pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe
T ▼ T ▼ T ▼
o. Oz o. O' Oz Oz
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8. During the past 4 weeks, how much did pain interfere with 
your normal work (including both work outside the home 
and housework)?
Not at all A little bit Moderately Quite a bit Extremely
□ 3 □ 3
9. These questions are about how you feel and how things have 
been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you 
have been feeling. How much of the time during the past 4 
weeks...
All of Most of Some of A little of None of
the time the time the time the time the time
T ▼ T ▼ ▼
Did you feel full of life?....... ......□ . ....... .......D z ....... ...... 0 , ...... ...... O ' ...... ..... O z
Have you been very nervous? ...... 0 , ..... ....... O z ...... ...... O z ...... ....... O ' ...... ..... O z
Have you felt so down in the 
dumps that nothing could 
cheer you up?......................... .....□ . ..... ...... O z ....... ......O z ..... .......O ' ...... ......O z
Have you felt calm and 
peaceful?................................ ......□ . ..... .......O z ..... ......  O z .... ........O ' ...... ......O z
Did you have a lot of energy? .....□ . ..... ......O z ...... ...... O z ..... .......O ' ...... ......O z
Have you felt downhearted 
and low?............................... ......□ . ..... .......O z .... ......O z ..... ........O ' ...... ...... O z
Did you feel worn out?......... ......□ . ..... .......Q z ..... ......O z ..... ........O ' ...... ...... O z
Have you been happy?......... ......□ ' ..... ....... □  z.... ......O z ..... ........O ' ..... ...... O z
Did you feel tired?................. ...... □ . ...... ......  O z .... ......  O z .... ....... O ' ...... ...... O z
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10. During the past 4 weeks, how much of the time has
your phvsical health or emotional problems interfered with 
your social activities (like visiting with friends, relatives, 
etc.)?
All of Most of Some of A little of None of
the time the time the time the time the time
▼ ▼ ▼ T T
□  z □  z □>
11. How TRUE or FALSE is each of the following statements for 
you?
Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definitely
false
T T T T T
I seem to get ill more 
easily than other people........ ........ □ . ....... ......O z ...... ....... O z ..... ........ O '.. . . ........ O  z
I am as healthy as 
anybody I know ...................... ........ □ . ....... ......O z ...... .......O z ..... ........O' . . . . ........O  z
I expect my health to
get worse ................................. ........ □ ........ ......O z ...... ....... O z .... .........O '.. . . .........O  z
My health is excellent......... ........ □ . ....... ...... O z ...... ....... O z .... ........ O '.. . . ........ O  z
Thank you for completing these questions!
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Appendix 3 Brief Pain Inventory
Brief Pain Inventory (Short Form)
1. Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains, and 
toothaches). Have you had pain other than these everyday kinds of pain today?
□  Yes G N o
2. ttie diagram, shade in the areas where you feel pain. Put an X on the area ttiat hurts the most.
Front Back
3. Please rate your pain by maMdng the tx)x beside the number that l>est dKcnt>es your pain at its 
in the last 24 hours.
□  O D 1  0 2  0 3  0 4  0 5  0 6  0 7  0 8  Q S  □  10
No Pain As Bad As
Pain You Can Imagine
4. Please rate your pain by narking the box beside the number that best describes your pain at its 
UJJ21 in Ihe last 24 hours.
□  o D i  0 2  0 3  0 4  O s  0 6  □ ?  Da O s  Dio
No Pain As Bad As
Pain You Can Imagine
5. Please rate your pain by marking the box beside the number that best descrities your pain on the
□  O Ol  0 2  0 3  0 4  0 6  0 6  0 7  0 8  O^ □  1°
No Pain As Bad As
Pain You Can Imagine
6. Please rate your pain by marking the box beside the number that tells how much pain you have
OO O l  0 2  0 3  0 4  0 5  0 6  0 7  0 8  0 9  OlO
No
Pain
Pain As Bad As 
You Can Imagine
Page 1 of 2
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7. What treatments or medications are you receiving for your pain?
8. In the last 24 hours, how much relief have pain treatments or medications provided? Please 
mark the box below the percentage that most shows how much Q j ^ y o u  have received.
0% 10% 
□ □
No
Relief
20% 30% 40% 50% 60% 70% 80% 90% 100%
□ □ □ □ □ □ □ □ □
Complete
Relief
9. Mark the box beside the number that describes how, during the past 24 hours, pan has interfered 
v^h your:
A. G eneral Activity
□  o D i
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O i o
Completely
Interferes
□  o O l
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O i o
Completely
Interferes
□  o O l
Does Not 
Interfere
0 2 ' 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O i o
Completely
Interferes
□  o O l
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O i o
Completely
Interferes
1
n o . Ol
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O i o
Completely
Interferes
□  o  □  1
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O  10
Completely
Interferes
1
□  o □  1
Does Not 
Interfere
0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 O  10
Completely
Interferes
Copyright 1991 Chartes S Cleeland, PhD 
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